

Ruperto-Carola University of Heidelberg, Germany

### German Cancer Research Center, Heidelberg Master Degree in Physics

Master Thesis

## Efficacy Of Dose Painting On Uncertain Biological Tumor Maps For Head And Neck Cancer Treatment

Author

Alexander Runde

Matr. 123456

Supervisor

Co-Supervisors

Prof. Dr. Uwe Oelfke

Dr. Emily Heath & Dr. Harald Keller

Academic Year 2011/2012

 $I\ dedicate\ my\ work\ to\ my\ family.$ You gave me the support to make a difference in other peoples lives.

 $I\ love\ you$ 

## Abstract

The term dose painting has been around since the year 2000 and has been coined by C.C. Ling as a new way to combine biological imaging and radiation therapy to improve treatment planning. This approach incorporates various biological input parameters that increases survival in tumour cells. Hypoxia has been identified as one of the major reasons for the failure of local tumour control in head and neck cancer. The lack of oxygen pronounces DNA repair from radiation damage from ionizing radiation, which leads to higher radioresistance in such hypoxic tumour regions. Dose painting can help to overcome hypoxia by increasing the dose to account for higher radioresistance. This thesis will introduce a new way of dose painting using the biological effect (biological dose painting) to overcome the treatment deficiencies created by hypoxia. Ten head and neck cancer patients with clinically approved plans from the Princess Margaret Hospital (Toronto, Ontario, Canada) have been used to apply biological dose painting under isotoxic treatment of critical structures to show feasibility of the new approach. Afterwards the deployed models are examined in terms of their model parameter uncertainties to assess the robustness of biological dose painting. This work shows, that biological dose painting is feasible and compensates for changes in radioresistance caused by hypoxia.

# Acknowledgements

Thanks and what not ...

# Table of Contents

1	Intr	troduction				
2	Phy	sical F	Principles	3		
	2.1	Energ	y loss of photons in matter	3		
		2.1.1	Photoelectric effect	4		
		2.1.2	Compton scattering	5		
		2.1.3	Pair production	6		
		2.1.4	Combined cross section for photons in matter	7		
		2.1.5	Interaction of Charged Particles with Matter	7		
	2.2	Radia	tion biology of photons	9		
		2.2.1	DNA radiation damage	9		
		2.2.2	The linear-quadratic model	9		
		2.2.3	Oxygen effect	11		
		2.2.4	Origin of hypoxia in tumours	13		
		2.2.5	Impact of hypoxia on cell survival	14		
		2.2.6	Assessment of chronic and acute hypoxia	18		
	2.3	Treatr	nent planning	19		
		2.3.1	Dose delivery with IMRT	19		
		2.3.2	Treament planning with KonRad	19		
		2.3.3	Physical Objective function	20		
		2.3.4	Dose calculation & biological effect	21		
		2.3.5	Biological objective function	21		
3	Dos	e Pain	ting Based on PET Images	23		
	3.1	PET I	maging	23		

		3.1.1	$\beta^{\pm}$ decay	23
		3.1.2	Physical principle of PET	24
	3.2	Quant	diffication of hypoxia	27
		3.2.1	Radiopharmaceutical approach to hypoxia assessment	27
		3.2.2	Modelling hypoxia with FMISO	31
		3.2.3	Correlation of tumour hypoxia vs. FMISO uptake values	34
		3.2.4	Eppendorf polarographic needle electrodes	35
	3.3	Review	w of dose painting methods	35
		3.3.1	Binary dose escalation	36
		3.3.2	Functional dose escalation	36
		3.3.3	Dose painting by numbers via kinetic models	39
		3.3.4	MRI dose painting	40
	3.4	Novel	approach: biological dose painting	40
		3.4.1	Implementation of biological dose painting in KonRad	40
		3.4.2	Clinical tumour hypoxia	41
		3.4.3	PET imaging	42
	3.5	Imple	mentation of biological dose painting	44
		3.5.1	Creation of realistic artificial PET images	44
		3.5.2	Plan comparison	46
4	Feas	sibility	of Biological Dose Painting	<b>4</b> 9
	4.1	Patien	ats	49
	4.2	Applio	eation of biological dose painting	50
	4.3	Result	s	52
		4.3.1	Impact of modelling	52
		4.3.2	Delivery quality and feasibility of dose painting	52
		4.3.3	Nominal plan vs biological dose painting	54
	4.4	Discus	ssion	56
		4.4.1	Feasibility of biological dose painting	56
		4.4.2	High dose fractions	58
		4.4.3	Size of hypoxic volumes	58
	4.5	Concl	usion	59

TA	BLE	OF CONTENTS	III
5	Effic	cacy of Biological Dose Painting	61
	5.1	Model parameter uncertainties	61
		5.1.1 pO2 model	63
		5.1.2 Hypoxia reduction factors	64
	5.2	Results	64
	5.3	Discussion	65
	5.4	Conclusion	66
6	Out	clook: Improving Biological Dose Painting	67
	6.1	Understanding PET images	67
		6.1.1 Accuracy of PET images	67
		6.1.2 Temporal variance	68
		6.1.3 Reoxygenation & single image planning	68
	6.2	Interpretation of hypoxia	69
7	Sun	nmary & Conclusions	71
$\mathbf{A}$	Dos	se compensation for hypoxia	i
В	Pati	ient statistics	iii
Bi	bliog	graphy	vii

# Chapter 1

# Introduction

Here comes a super introduction

## Chapter 2

# Physical Principles

#### 2.1 Energy loss of photons in matter




Figure 2.1: Overview on the physical effect responsible for the energy loss of photons in matter. Photoelectric effect (left), Compton effect (middle) and Pair production (right).

In particle physics, the photon  $(\gamma)$  is the mediator for the electromagnetic force. It is neutral and has zero mass. The latter is by virtue of the gauge invariance of the photon field's Lagrange function in quantum field theory. The photon moves with the speed of light  $c \approx 3 \times 10^8$  m/s. Since it is electrically neutral, it will not lose energy via the Coulomb force when interacting with matter. Instead, photons will travel a particular distance before being annihilated. The energy transfer of photons to matter is a combination of three different physical effects: Photoelectric effect, Compton scattering and Pair production (cf. figure 2.1). All of them are involved in the gradual energy loss of the photon, but are dependent on the initial energy and material that the photon is passing through. The distance travelled by a photon in matter is governed by a statistical process depending on a linear attenuation coefficient  $\mu$ , describing the probability of the matter penetration by the photon. All three effects have a contribution

to its total travelling distance.

$$\mu = \tau + \sigma + \kappa \tag{2.1}$$

If electromagnetic radiation with incident intensity  $I_0$  travels through a material with absorption coefficient  $\mu$  and dimension x, the intensity at x is

$$I = I_0 \exp(-\mu x). \tag{2.2}$$

#### 2.1.1 Photoelectric effect

The photoelectric effect describes the emission of electrons from matter as a consequence of the absorption of a photon. This emission occurs only if the incident photon energy is larger than the binding energy of electron in the atom. In this case the photon is completely absorbed and the electron is emitted. If the photon energy is too low, the electron will not be able to escape the material as a photoelectron. After its emission, the photoelectron has the following energy

$$E_e = h\nu - E_b, \tag{2.3}$$

where h is Planck's constant  $h = 6.626068 \times 10^{-34}$  m<sup>2</sup>kg/s,  $\nu$  the frequency of the incident photon and  $E_b$  the binding energy of the electron within the atom. The photoelectric effect is dominant in the low energy regime within a few hundred keV. When a photoelectron is extracted, the corresponding absorber atom becomes ionized. The created vacancy is filled by an upper shell electron, which can generate characteristic X-ray photons. In some cases this process will emit an Auger electron instead of a photon.

The contribution of the photoelectric effect to the linear attenuation coefficient  $\mu$  is represented by the photoelectric absorption coefficient  $\tau$ . It is highly dependent on the atomic number Z [1]

$$\tau = \left(\frac{32}{E^7}\right)^{1/2} \alpha^4 Z^n \underbrace{\left(\frac{8}{3}\pi r_e^2\right)}_{\text{grad}} \quad \text{with} \quad n \in [4, 5]. \tag{2.4}$$

Here  $\alpha = 1/137$  is the electromagnetic coupling constant and  $\sigma_{\text{Th}}$  the Thomson cross section for elastic scattering. For materials with lower atomic numbers  $\tau$  is proportional

to  $Z^4$ . If the atomic number Z is larger than 10, then  $\tau \propto Z^5$ .

#### 2.1.2 Compton scattering

The Compton effect describes the scattering of a recoil electron by an incident photon. The photon is deflected through an angle  $\theta$  with respect to its incident direction. In contrast to the photon from the photoelectric effect, the probability of the Compton effect occurring increases with incident photon energy. A portion of this energy is transferred to the electron, which is assumed to be initially at rest. The scattered electron is called a recoil or Compton electron. The portion of energy that can be transferred to the Compton electron can vary from zero up to  $E = 0.8E_{\gamma}$  of the incident photon energy  $E_{\gamma}$ . The energy of the the scattered photon can be derived by equating the four-momentum vectors of the incident photon  $\mathbf{p}_{\gamma}$ , electron at rest  $\mathbf{p}_{e}$ , scattered photon  $\mathbf{p}_{\gamma'}$  and Compton electron  $\mathbf{p}_{e'}$ . The scattered photon then has the energy

$$E_{\gamma'} = \frac{E_{\gamma}}{1 + \frac{E_{\gamma}}{m_e c^2} (1 - \cos \theta)}.$$
 (2.5)

By introducing the Compton wavelength  $\lambda_C = h/m_e c \approx 0.0243 \times 10^{-10} \text{m}$  the change in wavelength is

$$\Delta \lambda = \lambda_C (1 - \cos \theta) \tag{2.6}$$

The contribution of the Compton effect to the total linear attenuation coefficient  $\mu$  can be calculated by deriving the Compton cross section [2]

$$\sigma = \frac{\pi r_e^2}{E} \left[ 4 + \frac{2E^2(1+E)}{(1+2E)^2} + \frac{E^2 - 2E - 2}{E} \ln(2+2E) \right]. \tag{2.7}$$

Here  $r_E$  is the classical electron radius  $r_E = e^2/m_ec^2 = 2.82 \times 10^{-15} \text{m}$  and E the energy of the incident photon divided by the rest energy of the electron  $m_ec^2$ . The Compton cross section has two special cases, called the Thomson and Klein-Nishina regimes. The case  $E/mc^2 \ll 1$  is defined as the Thomson regime, while  $E/mc^2 \gg 1$  is described by the Klein-Nishina regime. Both regimes are part of the asymptotic behaviour of eq. 2.7 [3]:

$$\sigma \to \begin{cases} \frac{8\pi r_e^2}{3} \left[ 1 - 2E + \frac{26}{5}E^2 + O(E^3) \right] & \text{for} & E \ll 1 \\ \frac{\pi r_e^2}{E} \left[ \ln(2E) + \frac{1}{2} + O(E^{-1}) \right] & \text{for} & E \gg 1. \end{cases}$$
 (2.8)

The higher the energy of the incident photon, the more energy is transferred to the recoil electron. In total the recoil electron receives the largest portion of energy from the photon in the lowest energy region. The Compton effect is dominant in the regime of a few MeV.

#### 2.1.3 Pair production

As soon as the incident photon energy exceed double the mass of an electron  $2m_e = 1.022$  MeV, pair production becomes possible. This effect occurs when the photon interacts with a heavy nucleus. The incident photon disappears and a positron electron pair is produced

$$\gamma \to e^+ + e^-. \tag{2.9}$$

Depending on the energy of the photon, both the electron and the positron will have kinetic energy to travel through matter around them. The positron normally travels a small distance until it interacts with another electron. In this interaction both particles are annihilated and two photons are created. The cross section for pair production can be extremely complicated if all occurring phenomenons are included, especially Coulomb, screening and radiative corrections. For radiation therapy it is sufficient to assume an increasing cross section  $\kappa$  for larger photon energies E. The differential cross section is represented by the corrected Bethe-Heitler formula

$$\frac{\mathrm{d}\sigma(Z,\varepsilon)}{\mathrm{d}\varepsilon} = \alpha r_e^2 Z \left[ Z + \xi(Z) \right] \left( \left[ \varepsilon^2 + (1-\varepsilon)^2 \left[ \Phi_1(\delta(\varepsilon)) - \frac{F(Z)}{2} \right] \right] + \frac{2}{3}\varepsilon \left( \varepsilon \right) \left[ \Phi_2(\delta(\varepsilon)) - \frac{F(Z)}{2} \right] \right)$$
(2.10)

where  $\varepsilon = E/E_{\gamma}$  with E being the total energy carried away by the electron-positron pair and  $E_{\gamma}$  the energy of the incident photon. The functions  $\Phi_i$  and F(Z) are parametrized functions for the screening effect of the electromagnetic field depending on the screening variable  $\delta(\varepsilon)$ . For small energies in medical physics, it is sufficient to assume a linear proportionality to the cross section

$$\tau \propto E$$
 (2.11)

Pair production becomes dominant if the energy of the incident photons is 10 MeV and higher.

#### 2.1.4 Combined cross section for photons in matter




Figure 2.2: Total cross section  $\mu$  in units of barn  $(10^{-28}\text{m}^2)$  in the region from 1 eV up to 10 GeV. For radiotherapy, the Compton effect is most prevalent, as the common energies are in the range of a few MeV.

Photoelectric effect, Compton scattering and Pair production are dominant for specific energy regions of the incident photon. The photoelectric effect is dominant in the range of a few keV, whereas the Compton effect becomes important at the MeV scale up to 10 MeV. Afterwards pair production becomes the largest contribution for the interaction of photons with matter. Conventional radiation therapy uses energy on a scale of a few MeV, which means that the Compton effect prevails for this application. Figure 2.2 shows the total cross section for the photon in the energy regime of 0 MeV up to 10 GeV.

#### 2.1.5 Interaction of Charged Particles with Matter

Charged particles exhibit different behaviours when interacting with matter. Interactions either occur via inelastic scattering with electrons or elastic scattering with a nucleus. Therefore the analytical form of the energy loss per path length is much more complicated, as it can only be computed from quantum electrodynamics. Bethe and

Bloch were the first to derive this equation [4]

$$-\frac{dE}{dx} = \frac{4\pi}{m_e c^2} \cdot \frac{nz^2}{\beta^2} \cdot \left(\frac{e^2}{4\pi\varepsilon_0}\right)^2 \cdot \left[\ln\left(\frac{2m_e c^2 \beta^2}{I \cdot (1-\beta^2)}\right) - \beta^2\right]. \tag{2.12}$$

The parameters in the Bethe-Bloch formula are defined as follows

- $\beta = v/c$  with v being the velocity of the particle and  $c = 3 \times 10^8 \text{m/s}$  the speed of light.
- E energy of the particle.
- x distance travelled by the particle.
- z,e particle charge in units of an electron charge.
- $m_e$  rest mass of the electron.
- n electron density of the target.
- I mean excitation potential of the target.
- $\varepsilon_0$  vacuum permittivity of the target material.

Charged particles are also able to lose energy via Bremsstrahlung, Cherenkov radiation or nuclear interactions. A simple form of equation 2.12 for electrons and positrons can be derived as well [4]

$$-\frac{dE}{dx} = \frac{4\pi}{m_e c^2} \cdot \frac{nz^2}{\beta^2} \cdot \left(\frac{e^2}{4\pi\varepsilon_0}\right)^2 \cdot \left[\ln\left(\frac{\tau^2(\tau+2)}{2(I/m_e c^2)^2}\right) + F(\tau)\right]. \tag{2.13}$$

 $\tau$  is the kinetic energy of the incoming particle measured in units of  $m_e c^2$ . The function  $F(\tau)$  can be calculated for positrons and electrons via an approximation:

$$F(\tau) = \begin{cases} 1 - \beta^2 + \frac{\tau/8 - (2r+1)\ln(2)}{(\tau+1)^2} & \text{for } e^-\\ 2\ln(2) - \frac{\beta^2}{12} \left(23 + \frac{14}{\tau+2} + \frac{10}{(\tau+2)^2} + \frac{4}{(\tau+2)^3}\right) & \text{for } e^+. \end{cases}$$
(2.14)

For charged particles, the linear energy transfer (LET) defines the energy transferred to a material as the particle travels through it. While equation 2.13 focuses on the energy loss per unit distance traveled by the particle, LET describes the energy transferred to the material surrounding the particle track with due regard to secondary electrons. LET is defined as

$$LET = \frac{dE_{\Delta}}{dx},$$
(2.15)

where  $E_{\Delta}$  is the energy loss due to the collisions of the charged particle with the material minus the kinetic energy of all secondary electrons with energy  $E > E_{\Delta}$ . The larger the LET, the more secondary electrons are induced, which creates a larger energy deposition in the material.

#### 2.2 Radiation biology of photons

#### 2.2.1 DNA radiation damage

Biological damage caused by ionizing radiation is closely linked to the damage response of DNA. DNA damage can be quantified by looking at the DNA strand breaks, caused by charged particle tracks. DNA itself is constructed as a double-helix structure consisting of two strands, which are connected by a hydrogen bond. The so called sugar-phosphate group is the 'backbone' of each strand. If a single strand is broken, it does not necessarily lead to cell killing, as the DNA is able to repair itself by using the opposite strand as a template for its repair mechanism. If the repair is incomplete or incorrect, it leads to DNA mutation. In most cases, single-strand breaks (SSB) can either be repaired or lead to mutation due to misrepair. Double-strand breaks (DSB), on the other hand, are more difficult to repair. If a break in two strands is created within a few base pairs of the sugar-phosphate backbone, it creates a DSB. These DSB are one of the main sources for lethal lesions in DNA, since they create cell kill, carcinogenesis or mutation due to DNA misrepair. DSBs can occur either through direct ionization, or free radicals, created by the incident radiation. The charged particle tracks forming DNA strand breaks for photons are usually created by electrons [5]. Figure 2.3 shows all different scenarios linked to SSB and DSB induced radiation damage in DNA.

#### 2.2.2 The linear-quadratic model

The linear-quadratic model describes the relation between exchange-type chromosome aberrations resulting from two separate DNA strand breaks and absorbed dose D [6]. This model relates an absorbed dose D within a voxel to its biological effect  $\varepsilon$ . The




Figure 2.3: Damage mechanism of single and double strand breaks in DNA through ionizing radiation. Single stand breaks are only assigned to radiation damage that is created by one particle track, while double stand breaks are generated either by two seperate single tracks or a single track creating single strand breaks in two DNA strands.

biological effect  $\varepsilon$  can be calculated by combining the radio response parameters  $\alpha_i$  and  $\beta_i$  with the absorbed dose  $D_i$  in the voxel i,

$$\varepsilon_i(D_i) = \alpha_i D_i + G\beta_i D_i. \tag{2.16}$$

Here G is the time dependent Lea-Catcheside dose protraction factor [7], which will be assumed to be G = 1 for further considerations. The radio response parameters  $\alpha$ and  $\beta$  are parameterizations of the DNA single and double-stand breaks emerging from radiation damage. The dose D, where contributions to cell killing from the linear and quadratic terms are equal is

$$D = \frac{\alpha}{\beta}.\tag{2.17}$$

In the linear quadratic model, radiation damage is categorized into linear and quadratic dose contributions. These contributions are dependent on the tissue that is irradiated. In table 2.1 and 2.2 different  $\alpha$  and  $\beta$  values are shown. The biological effect  $\varepsilon$  can be related to the survival fraction of clonogens after being irradiated with dose D.

$$S(D) = \exp(-\varepsilon) = \exp(-(\alpha D + \beta D^2)). \tag{2.18}$$

Ç	Parameter Data				
Study by	Tissue type	$D_{50}$ [Gy]	$\alpha/\beta$ [Gy]	$\alpha \ [\mathrm{Gy}^{-1}]$	$\beta \ [\mathrm{Gy}^{-2}]$
Cronqvist et al. [8]	Brain & temporal lobes	60	2	0.062	0.031
eronquior er an. [e]	Brainstem	65.1	2	0.062	0.031
	Chiasm	65.0	2	0.0511	0.0256
	Eyes	65.0	2	0.0407	0.0203
	Larynx	80.0	3	0.0281	0.0094
	Middle-external ears	65.0	3	0.0915	0.0305
	Optical nerves	65.0	2	0.0511	0.0256
	Parotids	46.0	3	0.0675	0.0225
	Spinal Cord	68.6	2	0.0407	0.0203
	Temporomandibular joints	70.3	3	0.0918	0.0306
	Trachea-esophagus	68.0	3	0.0708	0.0236
Eisbruch et al. [9]	Parotids	28.4	3	0.13	0.0433
Honore et al. [10]	Inner ears	50.0	3	0.0265	0.0088
Roesink et al. [11]	Parotids	39.0	3	0.0413	0.0138
Schultheiss et al. [12]	Spinal Cord	68.6	0.87	0.0577	0.0663
Withers et al. [13]	Subclinical disease	27.0	10	0.0554	0.0055

Table 2.1: Tissue parameters for organs at risk derived from various studies.

Therefore  $\varepsilon$  can be interpreted as the expected number of lethal lesions per cell, when irradiating the cell with dose D. When the initial number of tumour clonogens N is known, the tumour control probability (TCP) can be calculated:

$$TCP = \exp(-N \cdot S(D)) = \exp\left(-Ne^{-(\alpha D + \beta D^2)}\right). \tag{2.19}$$

TCP relates tumour size and radiation dose to the probability of local tumour control.

#### 2.2.3 Oxygen effect

Oxygen has been found to be one of the most important pharmacological agents that is able to alter the biological effect of ionizing radiation [18] [19] [20]. The tumour vasculature can be distorted, which can frequently lead to hypoxic regions which demand a higher dose to achieve the same radiation damage as under fully oxygenated conditions. The ratio of dose administered under hypoxic to fully oxygenated conditions needed to

Study	Information	Parameter Data		
Study by	Tissue type/cell	$\alpha/\beta$ [Gy]	$\alpha  [\mathrm{Gy}^{-1}]$	$\beta  [\mathrm{Gy}^{-2}]$
Carlson et al. [14]	Prostate	3.1	0.15	0.048
Cronqvist et al. [8]	Nasoph. cancer T1 & T2 Nasoph. cancer T3 & T4	10 10	$0.1124 \\ 0.0854$	$0.0112 \\ 0.0085$
Furusawa et al. [15]	HSG T1 V79	$5.1 \\ 0.52 \\ 9.2$	0.313 $0.0305$ $0.184$	0.184 $0.0585$ $0.02$
Kraemer et al. [16]	Chordoma	2	0.1	0.05
Stuschke et al. [17]	Head & Neck	10	0.25	0.025
Withers et al. [13]	Subclinical disease	10	0.0554	0.0055

Table 2.2: Tissue parameters for tumor tissue derived from various studies.

achieve the same biological effect is called oxygen enhancement ratio (OER).

$$OER = \frac{D_{\text{Hypoxic}}}{D_{\text{Aerobic}}}.$$
 (2.20)

For photons, in vitro OER values have been measured between 2.5 - 3.5 [6]. In general the higher efficiency of radiation damage in highly oxygenated regions of the tumour has been affiliated with the oxygen fixation hypothesis. When DNA is damaged by ionizing radiation it can be chemically seen as a DNA radical (DNA·). The DNA-radical will either react with an SH group to DNA-H, leading to chemical restitution, or with molecular  $O_2$ . The latter leads to the formation of a DNA-OO· radical, which then combines with another hydrogen to DNA-OOH. The damage fixation caused by a unrejoinable DSBs leads to cell death. In general the mechanism of the oxygen fixation hypothesis has a half-life of  $10^{-10}$ s for ion pairs and  $10^{-5}$ s for free radicals, which demands the the presence of oxygen in this timeframe after the interaction with incident radiation. Oxygen in tissue is generally bound in water  $H_2O$ . When photons interact with this compound, the following reaction is initialized

$$\gamma + H_2O \to H_2O^+ + e^- \xrightarrow{H_2O} H \cdot + H_3O^+ + OH \cdot$$
 (2.21)




Figure 2.4: HIF-1 $\alpha$  mechanism for the transcription of proteins in DNA that increase cell survival in tumour cells in hypoxic environments.

The OH· can either recombine with another OH· to for hydrogen peroxide  $(H_2O_2)$ , or with a DNA radical to form a non-reversable organic peroxide  $RO_2$ . This leads to a non-repairable state of the DNA radical, causing cell death. Therefore, abundance of oxygen leads to a chemical change in the radiation damage formed in the DNA. These reactions are limited, if tumour regions are hypoxic, yielding in a higher probability of DNA repair and recovery. The presence of oxygen 'fixes' (hence fixation hypothesis) the damage done by free radicals, creating permanent lesions leading to cell killing, carcinogenesis or mutation (which also can lead to lethal damage).

This mechanism leads to a connection between hypoxia and poor outcomes of radiation therapy. The OER has been shown to increase with higher oxygen partial pressures with a half maximum OER at 3 mmHg or 0.5% oxygen [21]. In general OER is affected by the nature of cellular radio sensitivity, incident radiation, oxygen tension in the considered volume, time of oxygen presence and the cell cycle, as the S-phase is more resistant.

#### 2.2.4 Origin of hypoxia in tumours

A healthy cell in normal tissue which is deprived of oxygen will die. Tumour cells on the other hand are generally exposed to chronic hypoxia as their growth will lead to lack of vasculature to supply inner regions with enough oxygen. Lack of oxygen can then lead to decreased radiation response and to an underestimated cell kill. This is also true for

chemotherapy as the poor perfusion can lead to limited access to certain tumour areas. The underlying biochemistry of hypoxia in tumours has become more and more complex with the appearance of accurate description of transcription factors. For hypoxia the hypoxia inducible factor 1 (HIF-1) is the transcriptions factor that leads to the higher cell survival. This is achieved by up-regulating more than 100 proteins that promote survival and especially the aggressiveness of the hypoxic tumour cells. The mechanism for HIF-1 in hypoxic and oxic conditions can be described as follows [22]:

- Oxic conditions: If oxygen is present with HIF-1 $\alpha$ , it becomes a hydroxyl. Afterwards it is transformed to a proteasome (regulator for protein concentration and degradation of misfolded proteins) via ubiquitination.
- Hypoxic conditions: If oxygen is absent, HIF- $1\alpha$  will transform into HIF- $1\beta$ . This is accomplished by the translocation of HIF- $1\alpha$  to the nucleus. HIF-1 is the heterodimer (complex of a nucleic acid and a protein) of HIF- $1\beta$ , which is the transcription factor for more than 100 hypoxia response elements on the chromosomes. All elements share a specific sequence (5'-TACGTG-3') that will activate more than 100 proteins supporting cell survival.

Figure 2.4 shows a detailed schematic description of the HIF-1 mechanism for increased cell survival of tumour cells in hypoxic environments. Hypoxia can occur in two different forms: Chronic and acute hypoxia. Chronic hypoxia is a consequence of oxygen consumption by tumour cells that are inadequately perfused due to the distance between the cancer cells and the nearest blood vessels. Acute hypoxia is the result of the temporary closing of blood vessels due to the malformed vasculature of the tumour [23]. Both hypoxia types contribute to general tumour hypoxia and the poor outcome of radio treatment. One of the major differences between these two hypoxia categories, is their time scale variance. While acute hypoxia will show larger fluctuations, chronic hypoxia is more stable. As both hypoxia types possess HIF-1 as its transcription factor, hypoxia tracers are not able to distinguish between them. A mathematical approach to a differentiation of acute and chronic hypoxia is discussed in chapter 2.2.6.

#### 2.2.5 Impact of hypoxia on cell survival

Hypoxia will decrease the radio sensitivity of tumour cells. In terms of the linear quadratic survival model, this decrease affects the radio response parameters  $\alpha$  and

 $\beta$ . Carlson et al. [24] introduced a method to incorporate the impact of hypoxia into the linear quadratic cell survival model by using only a single parameter. The number of cells, surviving after being irradiated with a dose D under aerobic conditions is

$$S(D) = \exp\left(\frac{\alpha_A}{\text{HRF}}D + \frac{\beta_A}{\text{HRF}^2}D^2\right). \tag{2.22}$$

Here  $\alpha_A$  and  $\beta_A$  are radio sensitivity parameters under aerobic conditions. For low-LET radiation,  $\alpha$  represents the quantity of lethally misrepaired and unrepaired double-strand breaks, and  $\beta$  represents the quantity of lethal exchange-type chromosome aberrations formed through binary misrepair of two separate DSBs [14]. As this work is using photon beams for treatment planning,  $\alpha_A$  and  $\beta_A$  are assumed to be the radio response parameters for photons  $\alpha_X$  and  $\beta_X$ . HRF is the hypoxia reduction factor, which a derived quantity from the current oxygen conditions in a voxel [25].

$$HRF = \frac{Km + p}{K + p} \tag{2.23}$$

The functional form of HRF resembles a sigmoidal shape as it describes the clinical data best. The two parameters driving the transformation of oxygen partial pressure values p are m, the maximum HRF and K, which can be interpreted by inserting p = Kyielding HRF = (m+1)/2. The HRF concept is equal to an approach used by Toma-Dasu et al. [26] using the OER. In general the distribution of oxygen partial pressure p in tumour cells is a diffusional process and is dependent on the distance to the capillary wall p(r) [27]. The model parameters K and m are generally unknown and have to be retrieved by fitting measured data. As HRF is basically built upon the same mathematical concept as OER, it is possible to reuse and transform measurements for OER. This can be done by dividing the maximum OER by the OER for each level of oxygenation. Table 2.3 gives an overview over all conducted searches for these model parameters and their respective mean values and standard deviations. The data from Carlson et al. [25] have been reused to calculate the error on the fit, as it was not part of the publication. While the maximum HRF value m value seem to be largely consistent to another, the K value has a large spread. One of the reasons for these deviations is that all measurements conducted by Cullen et al. [31,32] are from the 1970s and exhibit larger errors in contrast to the measurement from Carlson et al.. The combined values

Study by	m	K [mmHg]	Comment
Carlson et al. [25]#	$2.78 \pm 0.06$	$1.47 \pm 0.14$	cf. [28] [29] [30] [24]
Cullen et al. $[31]^*$	$2.79 \pm 0.20$ $3.04 \pm 0.13$	$3.27 \pm 0.35$ $6.16 \pm 0.76$	in vivo (attached) in vitro (attached)
Cullen et al. $[32]^*$	$\begin{array}{c} 2.78 \pm 0.25 \\ 2.82 \pm 0.15 \end{array}$	$1.98 \pm 0.49$ $4.03 \pm 0.61$	in vivo (suspension) in vitro (suspension)
Wouters et al. [33]&	$2.5~(\alpha)/3.0~(\beta)$	3.28	cf. [30] [29]

**Combined**  $2.82 \pm 0.05$   $1.94 \pm 0.13$ 

Table 2.3: Model parameters from different in vivo and in vitro studies. All studies used photons as radiation source to derive parameter data. Remarks: \*Ehrlich ascites tumor cells, # Values and error recalculated from original data and fit, & not included in combined value since no error was available. Error from the *Carlson et al.* was not available in the published article and has been calculated through a new fit with the original data supplied by David Carlson (cf. figure 2.5).

for K and m in table 2.3 have been computed with a weighted mean to account for the large error differences in all presented measurements

$$\overline{x} = \frac{\sum_{i=1}^{n} (x_i / \sigma_i^2)}{\sum_{i=1}^{n} i^n (1 / \sigma_i^2)}.$$
(2.24)

The error on the combined value is the variance of the weighted mean of all measurements conducted

$$\sigma_{\overline{x}}^2 = \frac{1}{\sum_{i=1}^n (1/\sigma_i^2)}.$$
 (2.25)

The impact of HRF in radiotherapy can be derived by understanding its impact on the delivered biological effect. As the HRF decreases the radio response to radiation damage, the delivered effect becomes smaller as  $\alpha$  and  $\beta$  are scaled down. To compensate for this, either of two things have to done, to account for the decreased radio sensitivity:

1. Increase dose to a value, where the delivered effect with decreased radio sensitivity is equal to the prescribed effect under aerobic conditions. The dose D to compensate for hypoxia can be calculate in terms of prescribed effect  $\varepsilon_P = \alpha_X D_p + \beta_X D_p^2$ 




Figure 2.5: HRF model fit to original data from  $Carlson\ et\ al.$  [25]. The new fit to the original data allowed an estimate on the error on K and m for the robustness analysis in the later part of this work.

and prescribed dose  $D_p$  (cf. Appendix A for derivation)

$$D = \text{HRF} \left[ \sqrt{\left(\frac{\alpha_X}{2\beta_X}\right)^2 + \frac{\varepsilon_p}{\beta_X}} - \frac{\alpha_X}{2\beta_X} \right]. \tag{2.26}$$

The dose is linearly scaled to the HRF within a voxel. If the usual prescription in a voxel is 70 Gy, a HRF of 2 implies that 140 Gy are necessary to create the same biological effect in this hypoxic area. As seen in table 2.3, the maximum HRF is  $m = 2.82 \pm 0.05$ . Therefore in fully hypoxic areas with p = 0 mmHg, the dose has to be increased with a factor of 2.82.

2. Administrate radio sensitizers to compensate for the decreased radio sensitivity. The effect on the biological effect can be summarized into the sensitizer enhancement ratio (SER). SER is dependent on the drug concentration c and the current oxygen partial pressure p(r), while the survival then reads as [25]

$$S(D) = \exp\left(\frac{\alpha_A \cdot \text{SER}}{\text{HRF}}D + \frac{\beta_A \cdot \text{SER}^2}{\text{HRF}^2}D^2\right). \tag{2.27}$$

The administration of radio sensitizers is not part of this work, but should be considered as another way of decreasing the radio desensitization of tumour cells via acute and chronic hypoxia. If general dose painting should not prove feasible due to high dose fractions induced by hypoxia, radio sensitizers can decrease the effects this mechanism.

#### 2.2.6 Assessment of chronic and acute hypoxia

As mentioned in chapter 2.2.4, hypoxia can be categorized into chronic and acute hypoxia. Inclusion of acute hypoxia can lead to overestimation of hypoxia since it is transient and is is subject to temporal variance. To quantify the fractions of chronic and acute hypoxia  $Wang\ et\ al.\ [34]$  proposed a model based on the SUV. The model assumes that both hypoxia types contribute to the total tracer uptake H

$$H = H_a + H_c, \tag{2.28}$$

where  $H_a$  is the contribution of the acute and  $H_c$  of the chronic hypoxia to the tracer uptake. To distinguish two hypoxia types with the Wang model, it is necessary to analyze two functional images (such as positron emission tomography, cf. 3) of the same patient. This is due to the fact that only acute hypoxia shows a large temporal variance, while chronic hypoxia is seen as a constant. The total uptake in two functional images is

$$H_i = H_{a,i} + H_c \quad \text{for} \quad i = 1, 2$$
 (2.29)

Afterwards, all uptake values in the same voxels from the two functional images are sorted into high  $H_h$  and small  $H_s$  readings. The fraction of high uptakes  $H_h$  with respect to acute hypoxia is denoted  $\omega = H_{ah}/H_h$ . Defining  $x = (H_h - H_s)/H_h$  gives the following relation

$$\omega = \rho x^{\beta}, \tag{2.30}$$

where  $\beta = 0.6$  is derived via Monte-Carlo simulation and  $\rho$  can be calculated via an iterative best fit to a Gaussian distribution. For voxels that have high readings  $H_h$ , the chronic contribution can be calculated via

$$H_{c} = (1 - \rho x^{\beta})H_{h}.$$
 (2.31)

#### 2.3 Treatment planning

#### 2.3.1 Dose delivery with IMRT

All treatment plans presented in this work are intensity modulated radiotherapy (IMRT) plans. IMRT has been proposed by Brahme et al in 1982 [35], while the clinical solution to the inverse IMRT optimization problem has been formulated by Webb in 1989 [36] inferring the minimization of a objective function via simulated annealing. The form of the objective function can differ in different treatment planning systems. Generally, objective functions are quadratic and describe the difference between a desired dose in a voxel from a dose prescription and the current dose calculated in the optimization step. Chapter 2.3.3 describes in more detail, how KonRad implements such an objective function for physical dose and biological effect optimizations. Due to the physical nature of the optimization problem, the quadratic function does not have a local minimum, which allowed the implementation of a fast gradient approach to find the minimum instead [37]. The delivery of IMRT has been shown by Convery and Rosenbloom in 1992 [38], which was later used for MLC based IMRT treatment [39].

The intensity modulation achieved in IMRT can only be accomplished laterally to the the incident beam direction for photons. For protons and heavy ions, the finite range of particles allows a three dimensional variation of the intensity modulation [40], also referred to as 3D IMPT.

#### 2.3.2 Treament planning with KonRad

All treatment plans in this work are optimized using the treatment planning system KonRad [41]. KonRad is able to optimize treatment plans with carbon ions, protons, photons, electrons. It is also possible to create a combination of those modalities into one treatment plan. The basis of KonRad's plan optimization is a dose matrix  $D_{ij}$ . It describes the dose that a doseburst j deposits in voxel i for a unity fluence. A doseburst can be described as the smallest field element that can be varied. In case of photons this is the smallest opening of an multi-leaf collimator (MLC). The dose  $D_i$  in voxel i is dependent on the number of dosebursts  $N_{\rm DB}$ 

$$D_i = \sum_{j=1}^{NDB} D_{ij} w_j. {(2.32)}$$

 $w_j$  is the weight of the doseburst j, while  $D_{ij}$  is the dose matrix described earlier. With the implementation of the dose matrix  $D_{ij}$  in KonRad it is possible to separate dose calculation from the optimization process. This enables KonRad to speed up the optimization process, since the dose needs no recalculation after each optimization step. While  $D_{ij}$  describes the physical dose, KonRad has been modified to calculate biological effect for carbon ions [42] and protons [43], as well as for Intensity Modulated Proton Therapy (IMPT) [44]. The optimization process in KonRad for IMRT uses the LBFGS-B code [45] as the quasi-Newton approach for the minimization of the objective function.

#### 2.3.3 Physical Objective function

Treatment planning with biological dose painting is implemented into the treatment planning system KonRad [41]. The optimization in Konrad minimizes an objective function F that is defined as the weighted sum of the objective functions for each volume

$$F(\mathbf{w}) = \sum_{v \in \text{Targets}} \left( p_v^U F_v^U(\mathbf{w} + p_v^O F_v^O(\mathbf{w})) + \sum_{v \in \text{OAR}} p_v^O F_v^O(\mathbf{w}). \right)$$
(2.33)

Here **w** is the vector of the weights defining the fluence of each the dosebursts. The quadratic objective function for each target and each OAR are weighted with individual penalty factors  $p_v$  that can be defined independently for underdose  $(p^U)$  and overdosage  $(p^O)$ . The physical objective function for a volume v is given by [46]

$$F_v^O(\mathbf{w}) = \sum_{i \in v} \left| D_i(\mathbf{w}) - \overline{D}_v^O \right|_+^2 \qquad F_v^U(\mathbf{w}) = \sum_{i \in v} \left| \overline{D}_v^U - D_i(\mathbf{w}) \right|_+^2$$
 (2.34)

where  $\overline{D}_v$  is the respective prescribed absorbed dose for volume v. The dose  $D_i(\mathbf{w})$  is the calculated dose according to

$$D_i(\mathbf{w}) = \sum_{j=1}^{N_{\rm DB}} D_{ij} w_j, \qquad (2.35)$$

with  $D_{ij}$  being the dose matrix, and  $N_{\text{DB}}$  the number of dosebursts. The function  $|x|_+$  is defined as 0 for  $x \leq 0$  and x if x > 0.

#### 2.3.4 Dose calculation & biological effect

Before the optimization, the dose matrix  $D_{ij}$  has to be calculated. This calculate has to be executed for every bixel j and voxel i. KonRad uses a finite pencil beam dose calculation model [41]. To account for biological properties in the biological optimization, the  $D_{ij}$  approach has been extended in this work. As the biological effect depends on the radio response parameters  $\alpha$  and  $\beta$  is it useful to introduce matrices. Due to mathematical reasons (cf. equation 2.36) it is important to store the square-root of the  $\beta_i$  in the  $\beta_{ij}$  matrix. This is due to the physical nature of radiation superimposition: If more than one doseburst hits a voxel i one needs to superimpose the effects of the radiation. For the radio response parameters  $\alpha$  and  $\beta$  the superimposition can be calculate in the following way [47] [42]

$$\alpha = \frac{1}{D} \sum_{i=1}^{N} \alpha_i D \qquad \sqrt{\beta} = \frac{1}{D} \sum_{i=1}^{N} \sqrt{\beta_i} D_i.$$
 (2.36)

By combing the synergistic effects from different dosebursts in biological optimization the total biological effect in voxel i is given by [42]

$$\varepsilon_i(\mathbf{w}) = \sum_{j=1}^N \alpha_{ij} D_{ij} w_j + \left(\sum_{j=1}^N \sqrt{\beta_{ij}} D_{ij} w_j\right)^2.$$
 (2.37)

Therefore the biological objective function is proportional to  $\mathbf{w}^4$ . Due to the nature of the higher order of the optimization function it is possible that in some cases the biological objective function is not convex [48].

#### 2.3.5 Biological objective function

To implement biological effect optimization, KonRad can be altered by introducing the biological effect  $\varepsilon = \alpha D + \beta D^2$  into the physical optimization function. The quadratic difference between the prescribed effect  $\overline{\varepsilon}_v$  and the actual effect  $\varepsilon_i(\mathbf{w})$  is minimized using the same approach [48]:

$$F_v^O(\mathbf{w}) = \sum_{i \in v} \left| \varepsilon_i(\mathbf{w}) - \overline{\varepsilon}_v^O \right|_+^2 \qquad F_v^U(\mathbf{w}) = \sum_{i \in v} \left| \overline{\varepsilon}_v^U - \varepsilon_i(\mathbf{w}) \right|_+^2 \qquad (2.38)$$

For each doseburst j that deposit a dose  $D_{ij}w_j$  in the voxel i it is necessary to calculate the linear quadratic model parameters  $\alpha_{ij}$  and  $\beta_{ij}$ .

## Chapter 3

# Dose Painting Based on PET Images

#### 3.1 PET Imaging

Dose painting tackles the inability of conventional radiation therapy to incorporate hypoxia into treatment planning by increasing the dose delivery to selected regions as indicated by images of tumour functional status. Positron emission tomography (PET) is a viable candidate for non-invasive hypoxia evaluation in tumour sites. The generation of PET images is based on the  $\beta^+$  decay of a radiopharmaceutical, which is accumulated in hypoxic regions in the body.

#### 3.1.1 $\beta^{\pm}$ decay

In contrast to the energy spectrum of the  $\alpha$  and  $\gamma$  decay, the energy distribution of the  $\beta$  decay is continuous. A continuous energy distribution is not compatible with a two body decay mechanism, which led to the postulation of a third particle by Pauli 1931 [?]. The missing particle, the neutrino, was found by Cowan and Reines in 1956 [?] explaining the continuous distribution of the  $\beta$  decay as it now was interpreted as a three body mechanism. The  $\beta$  decay can occur in three different versions.

1.  $\beta^+$  decay: For PET imaging, the  $\beta^+$  decay is the most important one. It occurs when a proton decays into a neutron. As the proton is stable ( $\tau_p > 2.1 \times 10^{29}$  years [49]), the  $\beta^+$  decay is only possible if the parent nucleus is in an excited

state. If the binding energy of the parent nucleus is less than that of the daughter nucleus, this decay will not occur. In general, the  $\beta^+$  decay scheme is as follows:

$${}_{Z}^{A}X \rightarrow {}_{Z-1}^{A}Y + e^{+}\nu_{e} + Q.$$
 (3.1)

 $\nu_e$  is the electron-neutrino and Q is kinetic energy that is shared with all three particles. X describes the parent nucleus and Y the daughter nucleus.

2.  $\beta^-$  decay: The  $\beta^-$  decay occurs if a neutron decays into a proton. In contrast to the  $\beta^+$  decay, this decay is more common as the mass of the neutron is slightly higher due to its quark constituents. Therefore the mean lifetime of a neutron is much lower with  $\tau = 881.5$ s [49]. The  $\beta^-$  decay schema proceeds as follows:

$${}_{Z}^{A}X \rightarrow {}_{Z+1}^{A}Y + e^{-}\overline{\nu_{e}} + Q. \tag{3.2}$$

3. Electron capture: If the parent nucleus is not able to provide the energy necessary for a  $\beta^{\pm}$  decay, it is possible that the nucleus will capture on of its orbital electrons. The electron itself usually originates from the K-shell to initialize the conversion of a proton into a neutron.

$${}_{Z}^{A}X + e^{-} \rightarrow {}_{Z-1}^{A}Y + \nu_{e} + Q.$$
 (3.3)

#### 3.1.2 Physical principle of PET

PET can be accomplished by administering a radionuclide tracer. In a biological environment, these radionuclide tracers undergo a  $\beta^+$  decay. The positron gradually loses energy until it combines with an electron. The formation of an electron with a positron is called *Positronium*. In general, the process of positron annihilation is more complex as it can happen in a variety of ways. About 2% of positrons can annihilate before reaching thermal equilibrium to form positronium [3]. If a positron reaches thermal equilibrium, the strong Coulomb field of the nucleus averts it from annihilating with inner shell electrons of the atoms. Therefore, formation of positronium can only happen in three different situations: combination with free electrons, weakly bound electrons of the atoms outer shell or within low electric potentials between atoms of the molecule. Positronium can be created in two different versions, which is dependent on the spin

3.1. PET IMAGING 25




Figure 3.1: Total cross section  $\mu$  in units of barn  $(10^{-28} \text{m}^2)$  in the region from 1 eV up to 10 GeV. For radiotherapy, the Compton effect is most prevalent, as the common energies are in the range of a few MeV.

configuration. The  $^1\mathrm{S}$  singlet state is called *parapositronium*, while the  $^3\mathrm{S}$  triplet state is called *orthopositronium*. Parapositronium has a half-life value of  $\tau \approx 125 \times 10^{-12}\mathrm{s}$  [49], creating a photon pair after its decay. In the centre of mass system of the Positronium at rest both photons are emitted back-to-back (emission angle of  $180^\circ$ ). The decay of parapositronium into two photons is more frequent due to its angular momentum. Orthopositronium has a spin of one and usually decays into three photons which is also more stable than it singlet brother with  $\tau \approx 140 \times 10^{-9}\mathrm{s}$  [49]. The dominant process for the creation of photon pairs for the reconstruction of PET images, is parapositronium annihilation, as its cross section is 372 times larger [50].

By measuring both photons from the positronium decay with a ring of detectors, it is possible to reconstruct a *line of response* (LOR). LORs are registered via coincidence detection. This means, if the PET scanner detects two photons within a set time window, a LOR is defined. The larger the density of LOR, the higher the accuracy in the reconstruction process of the PET image. Due to other physical processes and randomness of events, coincident detection can be divided into four categories, which can also be seen in figure 3.1:

- 1. True coincidence: If the LORs cross the interaction point of the annihilation.
- 2. Scattered coincidence: Photons may be scattered within the patient through the Compton effect. This leads to a shift in the LOR reconstruction. Due to their energy loss, it could be possible to reject these events since PET scanners operate in the energy regime of 350 keV up to 650 keV. The interaction of the photon via Compton scattering lowers the energy of the photon. Therefore, photons with larger scattering angles can be rejected to avoid scattered coincidences.
- 3. Random coincidence: Two annihilation events occur within a short time period, but only one photon from each interaction is registered in the PET scanner. Therefore one LOR is generated originating from two different annihilation events leading to random coincidence.
- 4. Multiple coincidences: If three or more photons are detected in the same time window in the PET scanner, multiple LORs can be reconstructed.

In addition to the uncertainties in coinciding photon pairs, there is another problem that stems from an idealization of the positronium formation process. In theory, positronium is at rest when it reaches thermal equilibrium. However, normally positronium is not at rest in the centre-of-mass system. The additional energy from the binding process with its electron partner as well as the moving centre of mass reference frame can lead to a difference in energy of the two gamma rays of about 10 eV leading to non-collinearity. Non-collinearity leads to a decay of positronium, where photons are not exactly back-to-back, which can lead to a mispositioned LOR. The usual deviation from the 180° back-to-back photon emission is about  $\pm$  0.25° [51].

## 3.2 Quantification of hypoxia

## 3.2.1 Radiopharmaceutical approach to hypoxia assessment

One of the major insights to hypoxia measurements via radiopharmaceutical tracers was achieved by the decryption of the N-alkyl-2-nitroimidazoles mechanism. This substance has been shown to be trapped in living cells that were hypoxic. Due to its electron affinity, the functional group of the 2-nitroimidazoles (-NO<sub>2</sub>) can combine with an electron  $e^-$  to form a radical anion (-NO<sub>2</sub>). In presence of O<sub>2</sub> within the cell, the oxygen will be able to accept the electron from the nitro anion radical as oxygen has a higher electron affinity. If this happens, the nitroimidazole can return to its original form. If the nitro anion radical is able to react with another electron, the present O<sub>2</sub> is not able to reduce the nitroimidazole radical to its original form. The lack of oxygen will reduce it to a highly effective alkylating agent (RNH<sub>2</sub>), as it will accept another electron. This mechanism leads to a higher cellular retention of the tracer.

Tracer uptake is measured in standardized uptake values (SUV). The SUV can either be computed on voxel-wise basis or over a region of interest. SUV needs three different parameters to be calculated:

$$SUV_i = \frac{c_i(t)}{c_0 \cdot m}. (3.4)$$

Here  $c_i(t)$  is the tissue radioactivity concentration in MBq/kg while  $c_0$  is the radioactivity concentration at the time of the tracer injection. m is the body weight of the patient. One of the reasons why SUV is not always a good means of measuring tracer uptake concentrations is related to m. While most authors use the body mass to normalize the SUV, others may use the lean body mass [52] or the body surface area [53]. Figure 3.2 shows all discussed hypoxia tracers used for PET imaging.




Figure 3.2: Chemical structure of common tracers used in PET. FMISO and Cu-ATSM are commonly used in current studies, while studies with FAZA, FETA and FETNIM are on the way. FDG can be administered as a hypoxia tracer but is usually deployed for the use staging.

#### **FMISO**

$$H_2O_2$$
 $OH O_2$ 
 $R-NO_2$ 
 $+e^ R-NO_2$ 
 $+e^ R-NO_2$ 
 $R-NO_2$ 
 $R-NO_$ 

Figure 3.3: Retention mechanism of FMISO in the environment of oxygen. Figure adopted from *Krohn et a.* [54].

In PET one of the most common hypoxia tracers is [<sup>18</sup>F]fluoromisonidazole (1-(2-nitroimidazolyl)-2-hydroxy-3-fluoropropane) or FMISO for short. Similar to misonidazole (MISO), FMISO will metabolize in the same way. Figure 3.3 shows the retention mechanism for FMISO. FMISO will use enzymes (xanthine oxidase, lipoxygenases and NADPH oxidases [54]) to create the single-electron product. While MISO is mainly metabolized in the liver, FMISO is not, due to its missing methoxy substituent.

The imaging protocol for FMISO is arranged in such a way that the imaging process will begin 90-120 minutes after the injection of the radiopharmaceutical (quantity depends on patients weight). During the imaging process of about 20 minutes, a venous blood sample is drawn to normalize the static PET image data to the <sup>18</sup>F concentration in blood. This is known as the tissue-to-blood ratio T/B. Normoxic tissues usually exhibit T/B = 1. Hypoxic tumour volumes are characterized by the maximum T/B, corresponding to the major hypoxic level. The hypoxic volume HV can be derived by adding up all voxels whose T/B is larger than a set threshold [54].

The general discussion around hypoxia imaging is related to its accuracy of predicting

correct pO2 values in tumour sites. Multiple studies have been conducted to prove or disprove a direct link between FMISO uptake and pO2 via invasive Eppendorf electrode pO2 measurements (cf. 3.2.4). Due to the number of positive correlations shown in multiple studies, this work will assume this correlation to be true. This will allow a direct interpretation of FMISO SUV uptake value as hypoxia in PET imaging.

#### **FDG**

In contrast to FMISO, 2-deoxy-2-<sup>18</sup>F-fluoro-D-glucose (FDG) is a non-imidazole imaging agent. FDG is generally used for staging. FDG uptake is dependent on the expression of proteins that are under control of HRF-1, which can, in some cases, be in good agreement with the hypoxia level. Multiple studies with direct pO2 measurements have shown that, in contrast to FMISO, FDG is unreliable when predicting hypoxia [55]. This is mainly because FDG is very sensitive to the metabolic state in cells. On the other hand the accumulation of FDG could also be used to derive the current metabolic state showing differences between normoxic and hypoxic cancer cells [56]. Multiple studies with the goal of showing a direct correlation between FDG uptake and hypoxia are inconclusive.

## Cu-ATSM

<sup>64</sup>Cu(II)-diacetyl-bis(N<sup>4</sup>-methylthiosemicarbazone) (Cu-ATSM) is a hypoxia imaging agent that uses a metal complex of radioactive copper. Cu-ATSM can be reduced in a hypoxic environment to [Cu(I)-ATSM]<sup>-</sup>. Due to its negative charge, it can be trapped within the cell. Multiple studies have been performed to show the hypoxia selectivity of Cu-ATSM retention toward cell hypoxia [57]. However a recent study with multiple cancer cell types has indicated that Cu-ATSM may not be a suitable hypoxia tracer for all tumour types [58]. The administration of Cu-ATSM plays a very important role in its ability to yield correct correlations between tracer retention and tumour hypoxia. Several studies showed that the tracer uptake of Cu-ATSM 4 hours after the injection will not correlate to FMISO uptake values, while a Cu-ATSM image after 16-20 hours will show a good correlation. Cu-ATSM and FMISO seem to yield common results, whereas FDG uptake is not correlated to Cu-ATSM in any way [59].

#### Other nitroimidazole hypoxia tracers

**FAZA:** In contrast to FMISO, 1-(5-deoxy-5-fluoro-(-D-arabinofuranosyl)-2-nitroimidazole (FAZA) is more hydrophilic. In general FAZA exhibits larger T/B as well as tumour-to-muscle ratios T/M. This implies a higher signal for hypoxic regions in tumours and better differentiation between a background signal [60]. In measurements with Eppendorf polarographic needles, FAZA has proven to be consistent with tumour hypoxia [61].

**FETA:** <sup>18</sup>F-fluoroetanidazole (FETA) was developed to circumvent metabolic side reactions from FMISO but was found to be a sophisticated hypoxia tracer. FETA has major advantages on the field of non-hypoxic degradation in vivo, as it appeared to be less metabolized [62].

**FETNIM:**  $^{18}$ F-fluoroerythronitroimidazole has been reported to show higher T/B ratios for hypoxic tumour regions than FMISO [63]. In a clinical study on the abilities of FETNIM for hypoxia imaging, similar correlations between tracer uptake and hypoxia have been shown [64]. Until now FETNIM studies have been performed with head and neck cancer patients only.

**EF:** The field of hypoxia tracer development is a large and constantly evolving field. Currently, multiple hypoxia tracers are developed as 2-nitroimidazole agents such as EF1 [65], EF3 [66] and EF5 [67]. A study by *Komar et al.* [68] showed that EF5 initial uptake is governed by blood flow, while the later phase uptake and binding is hypoxia-specific. Therefore EF tumour markers could hold new possibilities once approved.

## 3.2.2 Modelling hypoxia with FMISO

Hypoxia can be measured with the help of PET using a FMISO imaging agent as it has been found to be positively correlated with retention of nitroimidazol in hypoxic tumour cells. The degree of correlation between FMISO concentration (intensity) measured with EPT imaging and hypoxia is variable, but was generally found to be positively correlated. Therefore, in this work high FMISO retentions will be interpreted as highly hypoxic regions, whereas low FMISO retentions are considered more oxic. In a study performed by *Chang et al* [69] FMISO PET uptake values have been directly compared to Eppendorf polarographic needle measurements to derive a model, which is able to




Figure 3.4: Transformation of FMISO PET SUV to oxygen partial pressure derived from the parameters of the model developed by *Chang et al.* [69]. Dotted and dashed line show the impact of the error of the model parameter  $p_{50}=6.4\pm5.4$  mmHg with due regard to the steepness of the transformation function.

relate these two quantities. The oxygen partial pressure (pO2) of the voxel i can be derived by virtue of the FMISO retention  $I_i$ 

$$p_i = p_{50} \left( \frac{I_{\text{max}}}{I_i} - 1 \right). \tag{3.5}$$

 $I_{\text{max}}$  is the maximum intensity (tracer concentration) in a PET image in a fully hypoxic environment (p=0 mmHg), while  $p_{50}$  is the oxygen partial pressure when the FMISO retention is the half maximum value. In the study by *Chang et al.* [69]  $p_{50}$  could only be measured with low precision due to the high fluctuations in Eppendorf polarographic needle measurements

$$p_{50} = 6.4 \pm 5.4 \text{mmHg}.$$
 (3.6)

 $I_{\text{max}}$  on the other hand is dependent on the tracer and should be determined from to other clinical data, as this parameter could also be dependent on the tumour type and other factors.

Bowen et al. [70] proposed another approach to link tracer retentions directly to oxygen partial pressure values through electrochemical modelling. One of the major motivations to this approach was that tracer uptake and retention mechanisms in PET in vivo are difficult to compare. An electrochemical formalism was derived by describing the bioreductive retention mechanism of FMISO and Cu-ATSM under steady-state conditions to relate time-averaged activity concentrations to pO2 values. The approach works in two steps: First, tracer concentration is related to oxygen concentrations, which is transformed to pO2 values

$$pO2 = K_{H}(T) \cdot 760 \frac{mmHg}{atm} [O_2].$$
 (3.7)

The constant  $K_H$  is the Henry coefficient which itself is dependent on the solution and temperature. For FMISO and Cu-ATSM the different retention mechanism ultimately lead to different chemical transformation functions to calculate pO2 values from tracer uptake values. As the math and chemistry behind this electrochemical modelling is quite complex, the author will only present the final equation for FMISO

$$pO2_{\text{FMISO}} \approx \frac{K_{\text{H}}}{K_{\text{NR}}^3 K_{\text{O}_2}} \frac{760}{[\text{FRNO}_2^{\bullet -}(O)]} [\text{H}_2\text{O}].$$
 (3.8)

Here FRNO<sub>2</sub> $^{\bullet}$ -(O) represents the concentration of the FMISO that is trapped by hypoxia in the tumour.  $K_{NR}$ ,  $K_{O_2}$  are constants derived from chemical consideration. Bowen et al. also compared their electrochemical model to direct measurements with Eppendorf polarographic needles. In general this approach shows strong correlations with modelled distributions with lymph nodes, while primary tumour sites do not. Strong deviations in such volumes have been confirmed by another study by Piert et al. [71]. In the latter, FMISO uptake has been investigated in vivo in porcine liver. The SUV was calculated from 659 single tissue samples and compared with the regional hepatic oxygen delivery calculated from the regional arterial and portal venous flow. Measurements of 121 liver tissue samples allowed a predictions of oxygen partial pressure from FMISO SUV

$$FMISO = 1.05 + 6.7^{-0.117 \cdot pO2} \rightarrow pO2 = -4.49 \cdot \log_{6.4}(FMISO - 1.05). \tag{3.9}$$

Although this model includes more clinical data than the model by *Chang et al.* [69] it is less satisfactory as its functional form exhibits a singularity at 1.05. Furthermore,

this model should not be applied to head and neck cancer patients, as the measured maximum SUV= 2.28 extrapolates an oxygen partial pressure of p = -0.5mmHg, which is unphysical. Therefore the model from *Chang et al.* [69] will be deployed in this thesis.

## 3.2.3 Correlation of tumour hypoxia vs. FMISO uptake values

In general a clear correlation between hypoxia and tracer retention in patients cannot be assumed. Multiple studies have been conducted in this area to find correlation between FMISO uptake and hypoxia. A direct measurement with invasive Eppendorf polarographic needles have confirmed a positive correlation between FMISO uptake and hypoxia [72–76]. In a detailed investigation by Gagel et al. [74] multiple correlations of FMISO were cross referenced to direct Eppendorf measurements. While FDG did not exhibit any correlations to direct measurements, FMISO tumour to muscle ratios were found to be correlated. Although multiple studies point to the fact that hypoxia is correlated with FMISO uptake, it has also been shown that only human soft tissue exhibits such a correlation [77]. A study conducted by Mortensen et al. [78] examined the association between measured hypoxia defined by a FMISO PET image and Eppendorf pO2 electrodes. A total of of 18 patients was processed by creating virtual voxels as localization for pO2 electrodes as well as FMISO scans. In general, tumours could be categorized in three groups: Well oxygenated with good agreement between FMISO uptake and direct measurements, hypoxic tumours with the same outcome and hypoxic tumours that did not show any concordance between assays. In general more hypoxic tumours were measured to be more hypoxic with a direct measurement than with a FMISO PET scan. As head and neck tumours are generally more hypoxic, this could lead to an underestimation of the FMISO signal and to failure of local tumour control despite dose painting. Due to the number of positive correlations found between FMISO uptake and hypoxia, this thesis will make the assumption that FMISO uptake is positively correlated with hypoxia.

## 3.2.4 Measuring hypoxia with Eppendorf polarographic needle electrodes

PET imaging using on of the various hypoxia tracers described in chapter 3.2.1 is a non-invasive way to assess tumour hypoxic. An invasive method for direct measurements of the oxygen level of tissue and tumour volumes are Eppendorf polarographic needle electrodes. The technical structure of such an electrode can differ from the model, but it generally is manufactured as a stainless steel shaft with a lancet shaped tip. The tip contains a membranized polarographic recessed microcathode (gold wire).

The measurements conducted with such an electrode represent an average oxygen partial pressure of the probed environment. The average value includes all cells in the intercellular environment that are in the sampling range of the probe. This might also include necrotic as well as living tissue. The usual procedure of measurements with Eppendorf electrodes includes the administration of an anaesthetic (lidocaine) with a subsequent insertion of an indwelling cannula. Afterwards removal of the trocar (medical instrument with a sharply pointed end used together with a hollow cylinder to be introduced into blood vessels, especially for laparoscopic surgeries), the needle electrode can be guided through the tissue. One measurement consists of predetermined distance which is then moved step by step (size variable) through the tumour volume, which is done automatically. The more tracks are acquired, the smaller the error on the measured value.

## 3.3 Review of dose painting methods

The deployment of PET has increased in the past years, mainly because PET has revolutionized imaging by giving radiation therapist a tool for anatomic localization of functional abnormalities in the complex territory of tumours. PET is used for staging, detection of unknown primaries and monitoring of treatment results. Dose painting is one the major concepts that involves the usage of PET to improve treatment planning. All dose painting approaches use a functional image such as PET or MRI to derive a dose escalation in one or the other way to account for hypoxic regions in tumour volumes. The way how the escalation is calculated can vary. Until now, dose painting by numbers (DPBN) has been used to prescribe a physical dose to hypoxic tumour volumes. The way how additional dose is prescribed to a clinical dose can be determined in various ways.

This chapter will comment on all different dose painting methods used to overcome hypoxia.

## 3.3.1 Binary dose escalation

Binary dose escalation uses PET imaging to identify hypoxic tumours. If a lymph node or the primary tumour has a high tracer uptake value, it is considered to be hypoxic. The intensity of the imaging agent does not scale the additional boost that is administered in the this area. Therefore binary dose painting dose not incorporate any biological basis for the prescription. Multiple studies have been performed with this approach [79–81]. One of the major findings derived from binary dose painting is that dose escalations can be achieved in most patients without compromising the dose limits to critical structures. Some cases were considered not the be feasible with this approach as they had critical organs (brainstem or spinal coord) very close to the target volumes [79]. In a study performed by Chao et al. [80] using an Cu-ATSM imaging agent results showed feasibility of dose escalations in hypoxic sub volumes in head and neck cancer, without compromising OAR constraints. While the GTV was treated with a dose of 70 Gy, its hypoxic sub volume was treated with a dose of 80 Gy. Another study conducted by Lee et al. [81] using FMISO guided IMRT found that dose escalations could easily be increased to 84 Gy (based upon a 70 Gy original prescription) and up to 105 Gy in one patient, without exceeding dose limits for critical structures.

### 3.3.2 Functional dose escalation

Functional dose escalations use a prescription function to calculate dose escalations. The way how the functional image is interpreted and incorporated into the treatment planning process are quite different from their implementation.

• Cost function manipulations: : Rather than manipulating the dose prescription directly, this approach featured a dose efficiency  $e(\vec{x}) \in [0,1]$ , which was coupled with the dose-based cost function of the optimization algorithm to incorporate functional images such as PET. This way, the dose-based cost function  $F(d(\vec{x}))$  was replaced with  $F(d(\vec{x})e(\vec{x}))$  instead. The analytical form of  $e(\vec{x})$  is very important since it will directly alter the way how the biological image will change the results of treatment planning. In a study performed by Alber et al. [82] this function

was rather simple as it represented a linear transformation of the signal intensity above a signal threshold

$$e(\vec{x}) = \begin{cases} \frac{1}{D_{\text{Max}}} \left( D_{\text{p}} + \frac{D_{\text{max}} - D_{\text{p}}}{I_{\text{mean}} + I_{\text{max}}} (i(\vec{x}) - I_{\text{max}}) \right) & I \ge I_{\text{mean}} \\ 1 & I < I_{\text{mean}}. \end{cases}$$
(3.10)

Here  $D_{\text{Max}}$  is the maximum dose,  $D_{\text{p}}$  the prescribed dose,  $I_{\text{mean}}$  the mean intensity,  $I_{\text{max}}$  the maximum intensity of the functional image and  $I(\vec{x})$  the intensity at position  $\vec{x}$ . This simple prescription function is safeguarded against unreasonable dose escalations as it will use a linear prescription mechanism. On the downside, this functional prescription does not incorporate the underlying biology in a patient that can be acquired through PET.

• Direct dose escalations: Rather than manipulating the objective function in the treatment planning system to incorporate functional imaging it is possible to directly manipulate dose escalations. The magnitude of changes that are induced by such a dose escalation are dependent on the analytical form of the escalation function. Multiple studies have proposed different approaches to this problem.

Bentzen et al. [83] used a linear interpolation method

$$D(I) = D_{\text{Min}} + \frac{I - I_{\text{Min}}}{I_{\text{Max}} - I_{\text{Min}}} (D_{\text{Max}} - D_{\text{Min}}).$$
 (3.11)

The dose escalation method proposed in equation 3.11 has also been used in an adaptive dose painting study performed by  $Duprez\ et\ al.\ [84]$  to create an FDG PET intensity based voxel-specific dose painting and has shown promising results in terms of feasibility. In a corresponding study,  $Madani\ et\ al.\ [85]$  determined the maximum tolerated dose (MTD) in a phase I trial with 21 patients. The escalated median dose was elevated up to 80.9 Gy in the CTV and 85.9 Gy in the GTV. All surviving patients did not show any grade  $\geq 4$  toxicity (life threatening or disabling side-effects) during treatment and follow-up, with the exception of mucosal ulcers.

In general equation 3.11 and equation 3.10 use the same kind of linear transformation to incorporate functional imaging into the optimization process. Nevertheless, the level of impact can be quite different, as the latter directly manipulates the optimization process in the objective function, while  $Bentzen\ et\ al.$  use dose scaling.  $Flynn\ et\ al.$  [86] used a slightly different formula, which incorporated a linear scaling to dose boost  $D_{\mathrm{Boost}}$  added on top of the original dose prescription  $D_{\mathrm{CTV}}$  in the clinical target volume

$$D(I) = D_{\text{CTV}} + \frac{I}{I_{\text{Mean}}} D_{\text{Boost}}.$$
 (3.12)

Physical dose painting that relies on a direct functional interpretation of the PET intensity, does not incorporate any considerations for the underlying biology. Therefore dose escalations are arbitrary as well as dependent on the functional form of the prescription function. Bowen et al. [87] performed a study on the sensitivity of IMRT dose optimization to the mathematical form of a biological imaging-based prescription function. Polynomial functions were tested to simulate a continuous prescription, while sigmoidal functions were used to account for a threshold scenario. In addition two concepts were checked with both functions:

- 1. Prescribe a constant integral dose in the primary tumor volume.
- 2. Prescribe a maximum boosted dose to the primary tumour volume without fulfilling any integral dose constraints.

Polynomial functions: In general, polynomial functions represent a continuous prescription scenario. Depending on the exponent in the polynomial, the behaviour of prescription may change in different situations. A dose distribution planned using a square root function most closely resembles its prescription due to the smoothing of the dose gradients at higher dose boosts and the tighter distribution of prescribed dose about its mean. Square root functions therefore prescribe lower dose escalations to larger fractions of the PTV. On the other hand, a dose distribution resulting from the use of a quadratic prescription function least resembles its prescription due to the sharpening of these same dose gradients at higher dose boosts and larger spread in the distribution of prescribed dose about its mean. Quadratic prescription functions prescribe a higher dose to a smaller volume fraction. Therefore it becomes more and more difficult to deliver conformal dose distributions as the boost volumes become smaller in comparison to the treatment volume [88].

Sigmoidal functions: This function type is compatible with a threshold scenario. Sigmoidal functions are shaped with two parameters: slope and threshold position. Both parameters are not independent of each other, as changes in dose delivery are dependent on alterations in slope and the position of the threshold. Increasing the prescription sigmoid slope at low threshold position yields to boosting of an increasing volumetric fraction of the PTV, while imposing steep gradients at the edges. Shifting the threshold towards a more central position, the dependence on the prescription slope becomes significant. Each voxel is equally sensitive to the steeper dose gradients, which causes smearing of the delivered dose as well as severe overdosed and underdosed regions [88].

## 3.3.3 Dose painting by numbers via kinetic models

Although most of the dose painting methods above can be categorized under the term 'dose painting by numbers', all of them lack the direct connection to a biological motivation for dose escalation. In a planning study by Thorwarth et al. [89] hypoxia was incorporated into a new DPBN approach. Three plans were created to evaluate the outcome of DPBN: A conventional IMRT plan, a uniform dose escalation (binary dose painting) and hypoxia DPBN. The latter was nested into a planning framework by creating dose escalation factors (DEF) from a kinetic compartment model [90]. The model described the behaviour of FMISO trapped in hypoxic cells and its diffusion in interstitial space. This allows for a better identification of severely hypoxic and necrotic tissue than with SUV. DEFs were calculated with regard to local cell survival  $M_i$  through a TCP model [91]

$$M_i = \exp\left(\frac{b \cdot \mathrm{TR}_i}{\mathrm{VP}_i + c}\right),$$
 (3.13)

where  $TR_i$  and  $VP_i$  are the tracer retention and vascularization-perfusion parameters for the *i*th voxel. The parameters *b* and *c* are acquired through the TCP model. Once the local cell survival  $M_i$  is calculated, DEF can be calculated based on the mean radio sensitivity parameter of the linear quadratic model  $\alpha$ .

$$DEF_i = \frac{\alpha D}{\alpha D - \ln M_i}.$$
(3.14)

Here D is the prescribed dose in the tumour volume. In the corresponding planning study, dose escalation was limited to 2.4 Gy per fraction, which was equal to DEF=1.2.

DPBN via kinetic modelling assigns dose escalations of 2.2 Gy per fractions on small sub volumes that have a significantly higher survival due to hypoxia. DEF may vary on a larger scale from 1.03 up to 1.66, leading to problems with the limited dose of 2.4 Gy per fraction. This is mostly due to a combination of severe hypoxia and low vascularization and perfusion. This approach has been reevaluated in a later study by comparing predicted survival from the kinetic model with a FMISO PET image after 20 Gy direct evaluation [92].

## 3.3.4 MRI dose painting

missing [93]

## 3.4 Novel approach: biological dose painting

Hypoxia reduces radio sensitivity and if it is not properly accounted for, leads to overestimation of cell kill. With the help of the optimization of the biological effect and incorporation of HRF into the model, it is possible to overcome hypoxia and create an adaptive method to increase cell kill in those areas by dose escalations. The model applied in this approach has been described in detail in chapter 2 and are combined in this chapter a novel approach of biological dose painting.

## 3.4.1 Implementation of biological dose painting in KonRad

The first step in biological dose painting is to convert the SUV uptake values to oxygen partial pressure via equation 3.5. This oxygen partial pressure can then be transformed to a HRF for every voxel with equation 2.23. Afterwards, a prescribed biological effect is calculated based on the prescribed physical dose. In a third step, the optimization begins to use the quadratic biological function to find the best possible treatment plan with due regard to normal tissue constraints as well as the biological effect prescriptions. Within every optimization step, the delivered effect  $\varepsilon_D$  is evaluated for every voxel.  $\varepsilon_D$  is calculated with

$$\varepsilon_D = \frac{\alpha_X}{\text{HRF}}D + \frac{\beta_X}{\text{HRF}^2}D^2,\tag{3.15}$$

where D is the current dose in the voxel. The optimization stops if the relative value change of the biological optimization function is less than 0.01 in the last 6 optimization

steps. The resulting physical dose distribution is analyzed to make plan comparisons simpler

As seen in equation 2.26, the optimizer will compensate for hypoxia by scaling the dose linearly with the HRF. In most cases normal tissue constraints will limit the possibility of dose escalation in hypoxic volumes (cf. chapter 4).

## 3.4.2 Clinical tumour hypoxia

In a meta-study by Jens Overgaard [94] a total of 4805 patients with head and neck cancer were reviewed in terms of dose boosting in radiotherapy. In general, overall hypoxic modifications of radiotherapy will result in the rapeutic benefits as it increases local regional control. This was also found to be independent of the type of modification used to circumvent the high radioresistance of hypoxic tumour areas. In order to estimate a realistic treatment environment for dose painting the first step is to evaluate Eppendorf polarographic needle measurements in head and neck cancer patients. A total of 551 patients have been found through comprehensive literature search. In most studies, pO2 values were separately measured in primary tumour volumes and lymph nodes. Every study presented in table 3.1 (if not noted otherwise) has conducted an evaluation of regions with pO2  $\leq$  2.5mmHg and  $\leq$  5.0mmHg, as well as a mean pO2 value. In general primary tumours and lymph nodes do not seem to deviate in mean value or volume distributions of hypoxia. Therefore there should be no differentiation in treatment approaches for these two targets. The mean value pO2 value in head and neck cancer has been measured as  $10.36 \pm 2.04$  mmHg. The hypoxia levels have been measured as  $16.09 \pm 4.65\%$  with < 2.5mmHg and  $36.38 \pm 6.80\%$  with < 5.0mmHg. This shows that head and neck tumours are generally hypoxic and hold a small fraction of highly hypoxic cells, which could lead to failure of local tumour control. Likewise, the range of mean values and volume percentages measured can be very large. Therefore it is important to customize the treatment for every patient which requires a deeper understanding in the link between FMISO tracer uptake values and the underlying oxygen partial pressure (cf. chapter 3.2.3). One of the goal of this thesis is to proof feasibility of dose painting in head and neck cancer patients. Therefore, all patients presented in this work, will be treated as an average hypoxia patient. The following assumptions are made for all patients:

- Every patient investigated in this thesis is assumed to exhibit the same hypoxic properties.
- Only the gross tumour volume (GTV) is hypoxic.
- The GTV exhibits a mean oxygen partial pressure of 10mmHg. Sub volumes encompassed by the GTV hold voxels that are more hypoxic and represent the 5.0mmHg and 2.5mmHg levels (cf. chapter 3.4.2 for detail construction of hypoxic volumes).

As patients are treated with radiation, the underlying biology changes. In terms of hypoxia, the biggest impact is associated with reoxygenation. The investigations of Lartigau et al. [95] and Stadler et al. [96] have shown that reoxygenation can clearly be measured after 32 Gy and 30 Gy respectively. In the study by Lartigau et al. the mean oxygen partial pressure change up to 58%, while the size of the highly hypoxic volume ( $\leq 2.5$ mmHg) shrunk from 14% to 5%. The same behaviour was observed in the measurements of Stadler et al.. In primary tumour sites, the mean oxygen partial pressure increased up to 25%, while the  $\leq 2.5$ mmHg and  $\leq 5.0$ mmHg volumes did not see any decrease. However, hypoxic volume reduction can be deduced by looking at the decreased statistical error on the volume measurements.

## 3.4.3 PET imaging

A comprehensive literature search has been conducted to evaluate the uptake values of FMISO and FDG tracers in head and neck cancer. In total 122 patients with FDG and FMISO images have been investigated. Most of studies presented in table 3.2 have been able to examine the uptake values of FMISO and FDG. Tracer uptake was characterized by using the maximum and mean tissue radioactivity concentration  $c_i(t)$  to derive SUV. In general FDG uptake is higher than FMISO. Mean FDG SUV have been measured as  $SUV_{\rm mean} = 3.75 \pm 0.24$ , while maximum SUV is  $SUV_{\rm max} = 9.63 \pm 1.1$ . For FMISO these values can be quantified with  $SUV_{\rm mean} = 1.76 \pm 0.16$  and  $SUV_{\rm max} = 2.28 \pm 0.32$ . The found results for PET images with FDG and FMISO are used to make the following assumptions for further investigations in this thesis:

PET images will are assumed to represent FMISO uptake distributions.

Study Ir	Study Information			pO2 Data [Range]	
Study by	Type	Patients	Mean [mmHg]	$\leq 2.5 \text{ mmHg } [\%]$	< 5.0 mmHg [%]
Becker et al. [97]	PT LN M	23 30	$12.37 \pm 10.18 \ [0.2-58.5]$ $13.71 \pm 12.94 \ [1.9-50.3]$ $43.78 \pm 10.11 \ [20.8-67.7]$	$18.03 \pm 22.54 [0.0-73.1]$ $18.56 \pm 21.92 [0.0-66.0]$ $0.36 \pm 0.94 [0.0-5.1]$	$25.97 \pm 38.64 [0.0-86.2]$ $27.86 \pm 25.78 [0.0-88.5]$ $0.95 \pm 1.45 [0.0-7.6]$
Lartigau et al. [98]	LN	6	$14.67 \pm 11.86 \; [0.0\text{-}39.0]$	$18.95 \pm 30.04 \; [0.0\text{-}100.0]$	ı
Lartigau et al. [95]	$\overset{\text{C}}{\text{C}}(32~\text{Gy})$	14	$18.37 \pm 12.81 \ [1.5-38.0]$ $28.92 \pm 28.77 \ [3.0-100.0]$	$14.11 \pm 18.02 [0.0-60.0]^*$ $4.89 \pm 8.74 [0.0 - 30.0]^*$	1 1
Nordsmark et al. [99]	Ö	397	$10.375 \pm 3.57 \ [0.0-62.0]$	$16.26\pm9.01[0.0\text{-}95.0]$	$33.50 \pm 14.24 \ [0.0-100.0]]$
Stadler et al. [96]	PT LN PT (30 Gy) LN (30 Gy)	2 21 3 16	$7.50 \pm 5.50 \ [2.0-13.0]$ $19.48 \pm 15.33 \ [0.0-47.0]$ $9.34 \pm 3.40 \ [6.0-14.0]$ $10.0 \pm 11.13 \ [0.0-35.0]$	$25.50 \pm 24.5 \ [1.0-50.0]$ $23.24 \pm 20.47 \ [0.0-76.0]$ $26.34 \pm 12.12 \ [10.0-39.0]$ $35.75 \pm 23.38 \ [0.0-68.0]$	$38.50 \pm 31.5 \ [7.0-70.0]$ $33.67 \pm 26.68 \ [0.0-92.0]$ $38.00 \pm 9.89 \ [24.0-45.0]$ $46.32 \pm 22.90 \ [0.0-70.0]$
Combined (PT)		28	$9.10 \pm 2.79 \ [0.0-58.5]$	$24.64 \pm 9.79 \ [0.0-100.0]$	$37.37 \pm 9.17 \ [0.0-92.0]$
Combined (LN)		89	$12.77 \pm 6.28 \ [0.0-50.3]$	$24.38 \pm 11.62 \ [0.0-76.0]$	$37.37 \pm 9.17 \ [0.0-100.0]$
Combined (All)#		551	$10.36 \pm 2.04 \ [0.0-100.0]$	$16.09 \pm 4.65 \ [0.0-76.0]$	$36.38 \pm 6.80 \ [0.0-100.0]$

Table 3.1: pO2 values for different head and neck studies. All pO2 values were acquired with the help of Eppendorf polarographic needle measurements (if not stated otherwise). Errors are standard deviation of the given data and sample size. Combined data are gather through weight of standard deviation and number of patients screened. C = Combined (Tumor & Nodes), LN = Lymphnodes,  $M = Muscle Tissue, PT = Primary Tumor. Remarks: * <math>\leq 2.0 \text{ mmHg}, \text{ }^{\#} \text{ not including muscle tissue pO2 values}$ 

- The maximum SUV=2.28 is assigned to the highly hypoxic regions in head and neck cancer. Therefore, if the FMISO SUV is equal to 2.28, a 2.5 mmHg oxygen partial pressure is inferred in this voxel.
- To incorporate the maximum SUV correlation to 2.5 mmHg hypoxia levels, the pO2 model from equation 3.5 has to be modified to account for this assumption. This can be easily done by changing the  $I_{\rm max}$  to its appropriate value, such that an intensity of I=2.28 yields p=2.5 mmHg

2.5mmHg = 6.4mmHg 
$$\left(\frac{I_{\text{max}}}{2.28} - 1\right) \to I_{\text{max}} = 3.17 \pm 0.77.$$
 (3.16)

Just as with direct measurements of oxygen partial pressure, reoxygenation can be clearly seen in a study conducted by *Eschmann et al.* [100]. It was found that the FMISO uptake after a total dose of 45 Gy decreased about 30%, while the range of FMISO SUV change from 1.7-4.4 to 1.4-3.0. As lower FMISO retention is directly linked to higher oxygen partial pressure, it can be concluded that reoxygenation has occurred.

## 3.5 Implementation of biological dose painting

A reasonable implementation of biological dose painting for clinical head and neck cases depends on the assumptions made for this approach. First and foremost, all assumptions made in chapter 3.4.2 and 3.4.3 are applied for this thesis to show feasibility of biological dose painting. One of the most important assumptions in this regard, is the way how hypoxia is modelled in head and neck patients. This chapter will deal with the clinical implementation of hypoxia in head and neck cancer as well as methods to compare clinically approved plans to biologically dose painted plans.

## 3.5.1 Creation of realistic artificial PET images

No FMISO images were available for the 10 patients in this study. Therefore, the only available method at present is to artificially created such PET images. A small tool has been constructed to generate PET images based on the patients volumes of interest. *PETCreate3* is C based fast PET image generator coupled with a point-in-polygon (PIP) algorithm. A number of PIP algorithms has been developed after its

Study	Study Information		FDG Uptake	FDG Uptake Data [Range]	FMISO Uptak	FMISO Uptake Data [Range]
Study by	Tracer(s)	Patients	Mean [SUV]	Maximum [SUV]	Mean [SUV]	Maximum [SUV]
Eschmann et al. [100]	FMISO FMISO (45 Gy)	14 14	1 1		$2.56 \pm 0.75  [1.7-4.4] \\ 1.99 \pm 0.44  [1.4-3.0]$	1 1
$Gagel\ et\ al.\ [75]$	${ m FMISO/FDG}$	16	$8.14 \pm 3.58 \ [3.3\text{-}17.4]$	$9.98 \pm 4.60 \ [4.6-20.0]$	$1.76 \pm 0.37  [1.2-2.2]$	$2.07\pm0.4716 [1.4\text{-}3.0]$
Komar et al. [68]	FDG	13	$6.14 \pm 3.01 [2.6\text{-}14.1]^{\&}$ $6.14 \pm 3.01 [2.6\text{-}14.1]^{\#}$	$8.94 \pm 4.49 \ [4.2-22.1]^{\&}$ $6.33 \pm 1.78 \ [4.2-8.5]^{\#}$	1 1	1 1
Lehtiö et al. [101]	FDG	20	$13.07 \pm 5.76 [5.3-28.8]^*$ $9.70 \pm 3.64 [5.7-16.2]^{\#}$ $11.94 \pm 3.14 [7.2-19.0]^{\&}$	1 1 1	1 1 1	1 1 1
Nehmeh et al. $[102]$	FMISO/FDG	14	34.1	$28.70 \pm 38.36 \ [7.3-136.6]$	2.9	$2.86\pm0.63 [1.9\text{-}4.5]$
Thorwarth et al. [103]	FMISO/FDG	12	$3.39 \pm 0.24  [3.0-3.9]$	$9.38 \pm 1.16 \ [7.9-12.1]$	$1.22 \pm 0.19 \; [0.9\text{-}1.5]$	$2.09 \pm 0.59  [1.4\text{-}3.2]$
Combined		122	$3.75 \pm 0.24 \ [2.6-34.1]$	$9.63 \pm 1.10 \ [4.2-136.6]$	$1.78 \pm 0.16 \ [0.9-4.4]$	$2.28 \pm 0.32  [1.4-4.5]$

patients. Errors are standard deviation from data in corresponding study. Remarks: \* Combined SUV uptake (Primary Tumor Volume & Lymphnodes), # Metastasis/Lymph Nodes, & Primary Tumor. Table 3.2: Uptake values for FMISO and FDG PET images from different studies and measurements conducted in head and neck

early description in 1974 [104]. *PETCreate3* uses a winding number algorithm, which utilizes the fact that the sum of all angles formed by the point of interest with the constituent points of a polygon will add up to multiples of  $2\pi$ , if the considered point lies within the polygon.

The construction of hypoxic volumes in all presented head and neck patients is based on the GTV. The GTV has been assumed to be hypoxic with pO2 = 10 mmHg. Smaller hypoxic sub volumes representing the 5.0 mmHg and 2.5 mmHg hypoxia levels are created by applying negative safety margins to the GTV. The volumes are created with the virtual treatment planning software VIRTUOS. As GTVs can differ in size and form, the accuracy of this construction mechanism can fluctuate, as the smallest applicable safety margin in VIRTUOS is 1 mm.

The general goal of this approach is to create volumes with properties shown in table 3.3. Together with the pO2 model, the hypoxia levels of 2.5 mmHg and 5.0 mmHg represent specific HRF values, which can also be seen in the table 3.3. In case of a clinical dose prescription of 70 Gy a hypoxic volume with an oxygen partial pressure of 2.5 mmHg has to be treated with a dose of D = 126 Gy to achieve the same biological effect as under aerobic conditions.

#### 3.5.2 Plan comparison

In radiotherapy, direct plan comparison features dose volume histograms, as well as dose distribution evaluations. In dose painting though, the biological effect is more important then the physical dose. This thesis proposes using biological effect volume histograms (eDVH) to compare different plans. As seen in previous chapters, hypoxia and their

pO2 (VOI)	HRF	Clinical % of GTV
$\leq 2.5 \text{ mmHg (GTV}_{2.5})$	$1.80 \pm 0.04$	$16.09 \pm 4.65$
$\leq 5.0 \text{ mmHg (GTV}_{5.0})$	$1.51\pm0.03$	$36.38 \pm 6.80$
$\approx 10.0 \text{ mmHg (GTV)}$	$1.30 \pm 0.01$	100

Table 3.3: HRF values for different hypoxic regions in head and neck patients. Parameters for calculations for HRF<sub>0</sub> are  $m=2.82\pm0.05$  and  $K=1.94\pm0.13$  mmHg. Errors calculated via error propagation method.

derived HRF distributions will change the results of radiotherapy and therefore the eDVH as well. However a direct comparison of the biologically dose painted plan with a nominal biological optimization is not feasible, as the latter assumes a fully oxic tumour volume. If such a comparison is made, the new approach will always be disadvantageous with respect to a normal biological optimization. Therefore such a nominal biological optimization has to be evaluated on the underlying biological tumour maps derived with the biological dose painting. The delivered biological effect for a nominal biological optimization evaluated on a hypoxia map is then

$$\varepsilon = \alpha_{\rm H} D + \beta_{\rm H} D^2, \tag{3.17}$$

where  $\alpha_{\rm H}$  and  $\beta_{\rm H}$  are the hypoxic radio response parameters (decreased by HRF) and D is the delivered dose of the nominal biological plan. As the construction of hypoxic volumes has been focus to the GTV, this eDVH is only generated in the GTV (and therefore in the respective sub volumes GTV<sub>5.0</sub> and GTV<sub>2.5</sub>). By applying this approach, a comparison can be made between the following three plans:

- Biological dose painted plan on the hypoxia map derived from a FMISO PET image.
- Nominal biologically optimized plan without dose painting evaluated on the hypoxia map derived from the biological dose painted plan from a FMISO PET image.
- Nominal biologically optimized plan, assuming a fully oxygenated tumour environment.

## Chapter 4

# Feasibility of Biological Dose Painting

## 4.1 Patients

All patients presented in this work are diagnosed with head and neck cancer. Head and neck cancer has been identified as the sixth most common cancer worldwide [105]. Head and neck cancer can be categorized into five groups, named after the regions, where the cancer usually originates from: Laryngeal and hypopharyngeal cancer, nasal cavity and paranasal sinus cancer, nasopharyngeal cancer, oral and oropharyngeal cancer, salivary gland cancer [106].

The patients presented in this thesis have been diagnosed with oropharyngeal cancer. Access to treatment plan data for ten patients have been approved by the local Research Ethics Board of the Princess Margaret Hospital (Toronto, Ontario, Canada) for this dose painting study. Patients were originally treated with 70 Gy in 35 fractions and had a clinically approved plan available for direct comparison with plans generated with biological dose painting. Original treatment plans were generated with the *Pinnacle 3* treatment planning system (Philips Radiation Oncology Systems, Fitchburg, Wisconsin, USA). The following procedure was used to create plans with biological dose painting.

1. Create a nominal treatment plan with KonRad until an adjust plan constraints with Pinnacle plan. Plan quality was assessed by target volume coverage and sparing of organs at risk. The nominal plan is created with a biological optimization without a PET image. The critical organ dose limits for both plans are based

on the HN06 trial criteria [107]. Afterwards, the treatment plan is approved by an experienced clinical medical physicist.

- 2. Application of biological dose painting to create a nominal dose painted plan. Due to the additional dose delivered into the hypoxic volumes in the GTV, iso-toxic treatment planning becomes more difficult. In most cases, dose limits in OARs can be achieved by changing overlap priorities in *KonRad* to achieve a better treatment of critical structures. If dose painted plans are within limits of the HN06 trial or the clinically approved plan, they are again evaluated by a radiation oncologist or a physician.
- 3. Comparison between the approved nominal and biological dose painted plans created with *KonRad*. A detailed description of methods used to compare the different results are presented in chapter 3.5.2.

## 4.2 Application of biological dose painting

Biological dose painting has been applied to the above described patients. In a first step, the provided patients were imported into the virtual treatment planning software VIRTUOS. VIRTUOS transform clinical plans to a format that can be imported to KonRad. In a second step clinical target volumes are edited with the hypoxic sub volume construction based on the GTV (cf. chapter 3.5). As the geometry of every patient is different and the accuracy of the negative safety margin applied to create the sub volumes is 1 mm, it is not always possible to achieve the same sizes. All treated patients are listed in table 4.1. The nominal plan created in KonRad is based on the clinical plan generated with Pinnacle. The latter is approved by a radio oncologist and fulfills the dose limits of the HN06 clinical trial [107]. The first goal is to achieve an equally good or better plan with a biological optimization without a PET image in KonRad. All dose statistics for OAR and tumour volumes are attached in Appendix B, as the nomenclature and number of incorporated treatment volumes varies with every patient.

	Patient Information	Hypoxic volumes	volumes	Clinical pla	Clinical plan dose [Gy]		3iological dos	Biological dose painting [Gy]	
Patient No	Patient No $[ccm]$ $[ccm]$ $[ccm]$ $[ccm]$ $[ccm]$ $[ccm]$ $[ccm]$ $[ccm]$	GTV <sub>5.0</sub> [ccm]	$\mathrm{GTV}_{2.5} \ [\mathrm{ccm}]$	$\overline{D}_{\mathrm{GTV}}$	Dmax	$D_{ m max}$ (GTV)	$\overline{D}$ (GTV)	$D_{\max}$ (GTV) $\overline{D}$ (GTV) $D$ (GTV <sub>5.0</sub> ) $D$ (GTV <sub>2.5</sub> )	$D \text{ (GTV}_{2.5})$
1	124846	43380 (34.8%)	11698 (9.4%)	68.94	78.49	119.8	93.4	95.5	92
21	8689	2858 (32.9%)	,	72.19	76.32	88.3	81.9	84.3	1
က	70948	$31163\ (43.9\%)$	7805 (11.0%)	71.13	76.47	120.9	88.9	94.4	104.6
4	62626	24287 (38.8%)	$3389\ (5.4\%)$	71.39	76.78	112.5	80	98	8.96
ಸಾ	33984	13.831 (40.7%)	3380 (10.0%)	69.81	2.2	116.6	85.5	91.2	100.7
9	127365	$39528 \ (31.0\%)$	9278 (7.3%)	63.5	77.03	116.5	86.9	93.4	102.8
2	42119	12231(29.0%)	3902 (9.3%)	71.58	78.26				
∞	11342 (CTV70)	3939 (34.7%)	702 (6.2%)	71.54	75.91				

values for the hypoxic sub volume construction are  $GTV_{2.5} = 16.08 \pm 4.65$  and  $GTV_{5.0} = 36.38 \pm 6.80$ . Clinical plan columns Table 4.1: Patient information columns show patient ID as well as the size of the treated GTV in ccm. Hypoxic volume column sizes of GTV<sub>5.0</sub> and GTV<sub>2.5</sub> are based on the GTV (=100%) created through application of negative safety margins. The guidance show the mean dose and maximum dose in the GTV. Biological dose painting columns show the theoretical dose values for equal biological effect due to HRF. HRF values are  $HRF_{2.5} = 1.8 \; (GTV_{2.5}), \; HRF_{5.0} = 1.51 \; (GTV_{5.0}) \; \text{and} \; HRF_{10.0} = 1.3 \; (GTV).$ 

## 4.3 Results

## 4.3.1 Impact of modelling

As dose escalations are applied to the plan, critical structures have to be reevaluated with due regards to their dose limits set by the HN06 trial. The dose in hypoxic volumes is scaled linearly with HRF (cf. equation 2.26). Severely hypoxic voxels with less than 2.5 mmHg oxygen partial pressure will exhibit  $HRF_{2.5} = 1.8$ , while hypoxic volumes with less than 5.0 mmHg show  $HRF_{5.0} = 1.51$ . The GTV itself has been shown to be hypoxic as well with an average of 10 mmHg (cf. table 3.1). Therefore, the GTV is assigned to a value of  $HRF_{10} = 1.3$ . As the GTV size varies from patient to patient, the impact of biological dose painting can also vary. Patient 2 had a very small GTV, which did not allow a n adequate  $GTV_{2.5}$ . Therefore dose escalations in this patient are smaller as in patients that have both sub volumes available for treatment planning. Patient 8 did not have a GTV as the tumour size had been surgically reduced. In this case, the  $CTV_{70}$  has been used to create the hypoxic sub volumes. Table 4.1 shows all patients treated with the new approach of biological dose painting. Figure 4.1 shows a direct comparison of the GTV of the clinical plan with the GTV and hypoxic sub volumes of the dose painted plan.

### 4.3.2 Delivery quality and feasibility of dose painting

The general limitation of biological dose painting is set by the critical structures in a head and neck patients, which is also dependent on the structure, geometry and size of the GTV itself. Guideline for all biologically dose painted patients, was the iso-toxic treatment of critical structures. This means that none of them are allowed to exhibit a larger maximum dose (in case of serial structures) or a mean dose (in case of parallel structures). If the clinical plan did not fully utilize the HN06 trial dose constraints, while the biological dose painted plan did, it is still counted as an iso-toxic treatment. Table 4.1 shows the mean and maximum dose values for the GTV and its hypoxic sub volumes. The critical structures that limit the complete delivery of dose painting to the patient involve esophagus, parotids, mandible, larynx, cord and the neck region. This is due to the fact that most clinical dose constraints in these volumes are below 70 Gy. As soon as dose painting is applied, higher dose up to 126 Gy (in the GTV<sub>2.5</sub> are considered in the optimization process. In most cases the GTV overlaps with critical structures,




Figure 4.1: Dose volume histograms for the GTV of the clinical plan (green) and all volumes from biological dose painting: GTV (red),  $\mathrm{GTV}_{5.0}$  (blue),  $\mathrm{GTV}_{2.5}$  (magenta). Patient 2 did not have a  $\mathrm{GTV}_{2.5}$  as the  $\mathrm{GTV}$  was to small.

which leads to the high dose that does not comply to the iso-toxic treatment. Therefore overlap priorities have to be changed to guide the optimization to achieve the target dose constraints.

In most cases the  $GTV_{5.0}$  is reaches very good dose coverage, while the  $GTV_{2.5}$  suffer from colder spots in some cases. This is mainly because the  $GTV_{2.5}$  is particularly small in correspondence to the GTV and  $GTV_{5.0}$ , which usually permits the large dose gradients needed to achieve the desired dose. Generally speaking, the desired dose can not be achieved in most cases, as critical structures will limit complete delivery.

Figure 4.2 shows the ratio R of delivered biological effect to prescribed biological effect in the GTV. The general form of the R distribution does not change significantly in most patients. The R value for patient 1 is shifter more to 1, while patient 4 shows a larger discrepancy for the dose painted plan. This is mainly due to the fact that patient 4 had a special geometry of GTV and OARs which limited the dose delivery.

$$R = \frac{\varepsilon_{\text{delivered}}}{\varepsilon_{\text{prescribed}}} \tag{4.1}$$

If R = 1, the delivered effect is equal to the prescribed effect, while R > 1 implies an over delivery and R < 1 implies under delivery of biological effect in those voxels.

Generally feasibility of dose painting is only limited by critical structures in the way of the beam toward the GTV and hypoxic sub volumes. The maximum dose point is never achieved due to these limitations, which means that certain voxels are not treated adequately, while voxels that are in line with the beam and the  $GTV_{2.5}$  will receive a higher dose. Critical structures limiting the feasibility of dose painting, depend on the size and shape of the GTV itself.

#### 4.3.3 Nominal plan vs biological dose painting

To compare the effectiveness of biological dose painting to approved clinical plans, this thesis uses biological effect volume histograms (eDVH). The way, how eDVH are derived has been described in chapter 3.5.2.

Figure 4.3 shows a direct comparison of a biological dose painted plan and a clinical plan in the GTV for all patients treated with dose painting. The clinical plan does not incorporate the underlying hypoxic effect of radioresistance in the GTV, which leads to an overestimation of cell kill. The delivered plan from the combination of the under-




Figure 4.2: Ratio R of delivered biological effect in the GTV divided by the prescribed effect. If R > 1, the voxel is over dose, while R < 1 can be interpreted as under dose. R distributions show clinical plan (green) and dose painted plan (red).

lying tumour hypoxia and the clinical dose delivered into the GTV. Generally, mean biological effect of clinical and dose painted are almost equal. This is due to the fact that dose painting compensates for the hypoxia present in the GTV. However, delivery quality decreases, as the dose gradients become higher. This is especially reflected in the flattening of eDVH around the mean value for dose painted plans. Delivered plans eDVHs are derived from the combination of hypoxia maps and delivered dose from the clinical plan. This represents the biological effect achieved, if hypoxia is incorporated. The biological effect in delivered plans is always lower as the HRF decreases the mean delivered effect. The difference between the clinical plan the delivered plan in the eDVH in figure 4.3 shows the reason for local failure in head and neck cancer, as cell kill is overestimated as hypoxia is not incorporated in the planning process.


## 4.4 Discussion

## 4.4.1 Feasibility of biological dose painting

This work shows that biological dose painting is feasible while simultaneously conforming to dose constraints from an approved clinical plan. The implemented dose painting approach compensates for hypoxia derived from PET FMISO images by increasing the dose in such hypoxic volumes. In contrast to the delivered plan (derived from the hypoxia distribution from the PET image and the clinical plan), is able to achieve desired tumour control while sparing the OAR just as in the clinical plan. All plans did not achieve the anticipated maximum dose of 126 Gy based on the 70 Gy prescription of the clinical plan. This is mainly due to the following facts:

- The smallest hypoxic sub volume representing the 2.5 mmHg oxygen partial pressure is too small to generate the high dose gradients needed to achieve such a high dose points.
- There are OARs in the way from the incident beam to the hypoxic volumes. The
  constraints on the OAR will decrease the maximum deliverable dose to the hypoxic
  sub volumes.

The achieved biological effects with biological dose painting suffer from limitations from the OAR around the GTV and in between the incident beam and the hypoxic subvolumes. This leads to the flattening of the eDVH distribution, or in other words,



reduced through hypoxia is based on the clinical plan (green). Dose painting (red) is able to compensate for hypoxia by increasing Figure 4.3: eDVH of GTV for all treated patients with biological dose painting. The biological effect of the delivered plan (blue) the dose to such volumes. The dip in the eDVH for the delivered plan (blue) stems from the 2.5 mmHg hypoxia level.

57

a larger spread of biological effect when compared to the clinical plan without any hypoxia considerations. In comparison to the delivered plan, derived from the clinical plan, biological dose painting performs better than any conventional radiotherapy. The success of treatment in head and neck can be improved if dose painting is used clinically. This implies a better understanding of the functional imaging modality that is used to derive hypoxia. If the underlying hypoxia tumour derived from such an image is a realistic representation of the true pO2 distribution in a tumour volume, then dose painting could yield even better results. Chapter 6 takes a closer look on how this can be incorporated into the current treatment planning framework.

## 4.4.2 High dose fractions

The biological model deployed in this work invoke a dose above 100 Gy. Usually radiotherapy rarely surpasses this dose value. If the implications of the biological model are correct, then 126 Gy are needed to overcome the highly hypoxic regions of the tumour to achieve local tumour control. The problem that arises from such high dose values is the damage done in the tumour volume itself, as it generally disintegrates all tissue types. In a treatment plan with 30 fractions a dose of 4.2 Gy is needed to achieve such a high dose in the hypoxic sub volumes. This of course is not feasible as the skin becomes highly irritated and should be avoided for the sake of patient's wellbeing. Rather than delivering such a high dose plan in 30 fractions, it could be feasible to achieve biological dose painting in 35-40 fractions as the fraction dose is within acceptable limits.

### 4.4.3 Size of hypoxic volumes

Depending on the size of the GTV, the hypoxic volumes generated with the approach used in this work get smaller than feasible for general dose delivery. This is mainly due to the fact that the steps from the GTV<sub>5.0</sub> to the GTV<sub>2.5</sub> theoretically dose increase from 105 Gy to 126 Gy. If the hypoxic sub volume is too small, such dose gradients cannot be generated with normal photon delivery, while an approach with protons or carbon ions could yield a much better result. The size of the small hypoxic volumes can also be problematic while positioning the patient while the treatment. Small errors in positioning can lead to a larger dose in parts of the tumour that are less hypoxic, while the highly hypoxic volumes receive a smaller dose.

4.5. CONCLUSION 59

## 4.5 Conclusion

Biological dose painting is feasible for head and neck patients while conforming to clinical dose constraints. Dose escalations can be generated from a PET FMISO image and implemented into a treatment planning framework that accounts for hypoxia derived from a tumour map generated from such a function image. Dose delivery does not completely reach the desired maximum dose, but the biological effect delivered with biological dose painting compensated for hypoxia. The comparison with clinical plans show, that biological dose painting shows a huge advantage in treatment planning. The high dose needed to deliver dose painted plans should be split into more fractions to avoid complications with skin and improve the wellbeing of the patient during treatment.

## Chapter 5

# Efficacy of Biological Dose Painting on Uncertain Tumor Maps

The biological model deployed in this novel approach to dose painting encompasses four different parameters. While the  $I_{\rm max}$  is a parameter that is dependent on the tracer (here FMISO) and has to be adapted to clinical oxygen values from direct Eppendorf measurements. A robustness analysis was performed for biological dose painting to assess the impact of model uncertainties. For this, the approved biological dose painted plan on the mean model parameters was used to evaluate changes of biological effect on new tumour maps derived from model parameter combinations. Three parameters were evaluated within their standard deviation, which means that every parameters had a lower limit (mean - standard deviation), mean and upper limit (mean + standard deviation). Therefore,  $3^3 = 27$  plans have to be evaluated by comparing the eDVH distributions and their impact on the delivered effect from their underlying HRF distributions.

### 5.1 Model parameter uncertainties

This work will investigate all parameters involved in the calculation of dose escalation factors in hypoxic sub volumes. The theoretical implications of the errors on the model parameters  $p_{50}$ , K and m are shown in figure 5.1. The largest deviation in HRF transformation is given by the  $p_{50}$  parameters, while m and K have a smaller impact.




Figure 5.1: Impact of model uncertainties on the HRF derived from the signal of a PET FMISO image in the SUV range of 0 up to 3.17. The lowest impact on the HRF prescriptions is seen with K, while  $p_{50}$  and m introduces the largest HRF changes in the transformation model.

#### 5.1.1 pO2 model

The pO2 model from Chang et al. uses two parameters. The  $I_{\text{max}}$  parameters is a parameters, which can be adjusted to the latest pO2 measurements in any cancer geometry for a specific tracer. For head and neck cancer with FMISO, this value has been calculated to be  $I_{\text{max}} = 3.17$ . The other parameter is the  $p_{50}$  value, which represents the pO2 value where the PET intensity is  $I_{\text{max}}/2$ . This value has been measured by Chang et al. with a large error

$$p_{50} = 6.4 \pm 5.4 \text{mmHg}.$$
 (5.1)

As the error on this parameters is about 85% of the original value, it has a larger impact on these values in the theoretical framework that is relevant for the calculation of HRF. This has direct implications on the delivered effect as the  $p_{50}$  parameter governs the range of how PET intensities are interpreted as pO2 values.

Lower limit ( $p_{50} = 1 \text{ mmHg}$ ) The  $p_{50}$  is interpreted as the oxygen partial pressure, where the PET intensity is  $I_{\text{max}}/2 \approx 1.59$ . Therefore if the PET SUV is lower, the pO2 will be lower than 1 mmHg. The HRF in these voxels is then close to its maximum value, as the peak HRF is reached at 0 mmHg. Together with the mean parameter values m = 2.82 and K = 1.94, the HRF for 1 mmHg is HRF=2.2. Therefore, dose escalations based on a initial 70 Gy prescription are then D = 154 Gy.

Mean ( $p_{50} = 6.4$  mmHg) The HRF changes dramatically to HRF=1.42, as the K = 1.94 value plays a big role in the HRF transformation. The largest change in HRF is seen, as soon as the  $p_{50}$  value is larger than the K value. This is because, the HRF transformation function has sigmoidal shape and K is the threshold parameter. The dose boost based on a 70 Gy prescription is 99.4 Gy.

Upper limit ( $p_{50} = 11.8 \text{ mmHg}$ ) Here the HRF changes slightly to HRF=1.26 as the transformation function for HRF slowly reaches its plateau. By construction, the larger the pO2 values derived from the oxygen model, the lower the HRF. However, mathematically even muscle tissue (40 mmHg) exhibits HRF=1.08. This could imply, that the parameterization of the oxygen model deployed in this approach could be

gauged with another parameter (cf. chapter ??). The dose escalation based on a 70 Gy prescription is then 88.2 Gy.

#### 5.1.2 Hypoxia reduction factors

HRFs are dependent on two parameters. The m value as the maximum HRF value and K, which is the oxygen partial pressure at m/2. While m is a general scale for the HRF within a volume, the K value poses as a threshold value. In contrast to the pO2 model, all parameters deployed in the HRF model exhibit small errors. The K value shows an error of 1.7%, while m has an error of 6.7%. Therefore, the range of HRF caused by uncertainties is much smaller, than with the pO2 model.

#### 5.2 Results

Due to the fact, that the pO2 model directly interprets the PET intensity as oxygen partial pressures, it has direct implications on how the HRF transformation function computes HRF and their corresponding dose escalations in the biological optimization. As the  $p_{50}$  value approaches 1 mmHg, most voxels are seen as highly hypoxic, which implies high HRF values. Figure 5.2 shows the eDVH for all 27 plans (for patient 1), as well as the clinical and delivered plan for a representative patient. All eDVH curves are evaluated based on the dose painted plan with mean values. The previously discussed impact of  $p_{50}$  can be clearly seen by the clustering of eDVH lines around the 1 mmHg, 6.4 mmHg and 11.8 mmHg parameter values. The differentiation between both HRF transformation parameters K and m is marginally small. Nevertheless, small differences can be seen. The larger the K value, the more voxels are shifted to a larger HRF giving them a high radioresistance. As m is general scale for the HRF, a larger m value will stretch the HRF range, while smaller m parameters will bulge it. The different HRF generated from the model parameters therefore lead to an over and underestimation on the HRF values as well as the current oxygen partial pressure.

Generally speaking, planning robustness suffers from the large error on  $p_{50}$ , while K and m have small impact on the overall HRF distribution. The latter is due to the fact, that the errors to m and K are lower than 10%, while the error on  $p_{50}$  is eight times larger. Likewise, the pO2 prescription model has a larger range of values, as oxygen partial pressures are usually found between 0 mmHg and 40 mmHg (and more)

5.3. DISCUSSION 65

in a usual patient. Therefore, errors in this function have implications in term of value range.




Figure 5.2: Impact of model parameters uncertainties on the eDVH for patient 1 based on the approved biological dose painted plan with mean values for K, m and  $p_{50}$ .

#### 5.3 Discussion

When evaluated with uncertainties, the deployed model shows large differences in HRF distributions, which then lead to different hypoxia tumour maps. In comparison to the tumour map from the plan with mean parameter values, these maps represent scenarios, where the ignorance toward model uncertainties create an over or under estimation of oxygen partial pressures. If the tumour map derived from mean model parameters over estimates the HRF, then dose escalations are set too high in the optimization leading to bad treatment plans. On the other hand, if the mean plan underestimated oxygen partial pressures, dose escalations will not reach the level that is needed to achieve the

anticipated biological effect. However, it should be pointed out, that in both cases (over and underestimation of HRF) do not lead to a worse treatment plan than the clinical plan. This is due the fact, that the HRF values can never be lower than 1. Therefore, dose painting can only increase tumour control probability as it only increases (and never decreases) the dose value in a voxel based on the hypoxia map.

The largest impact on the HRF distributions is due to the large error on the  $p_{50}$  parameter from the pO2 model derived by *Chang et al.* as it has a big impact on the range of pO2 value extrapolated from the PET FMISO image. As the m and K parameters only show a small error, which 8 times smaller than the one on  $p_{50}$ . Therefore it would be desirable to obtain a better measurement on this parameter.

#### 5.4 Conclusion

The model used in this thesis for the calculation of dose escalations based on FMISO PET images lacks clear robustness as the error on the  $p_{50}$  parameter of the pO2 model from *Chang et al.*?? is extremely large. This leads to a wide range of possible HRF distributions that determine the dose escalations in hypoxic volumes. Other sophisticated pO2 models or a better measurement of the  $p_{50}$  value would increase the robustness of biological dose painting. However biological dose painting does not create plans that are worse than the clinical plan, as the HRF is limited to values larger than 1.

## Chapter 6

# Outlook: Improving Biological Dose Painting

#### 6.1 Understanding PET images

This chapter deals with the limitations of PET imaging to generate hypoxia tumour maps and will discuss possible improvements that can increase feasibility of biological dose painting.

#### 6.1.1 Accuracy of PET images

The resolution of PET images in clinical use is about X mm. As the characteristic scale for the transport distance of oxygen through tumour volumes is about X mm, this means that PET is not able to map the microenvironmental oxygen distributions of oxygen. Therefore, PET images only show a mean value of the underlying biology. Christian et al [108,109] showed in a study, how the limitations of PET imaging change biological adaptive IMRT assessed in animal models for FDG by comparing a PET image with an autoradiograph image (resolution of  $100\mu$ m). After registration both images were segmented on a threshold-based method, that allowed the creation of equal analysis volumes for both images. The comparison between both images showed that PET images have a low matching value (39%) when compared to autoradiograph images. The lower the threshold was set to create smaller analysis volumes, the matching value increased. Therefore, higher PET resolution can improve the matching to an autoradiograph image.

In general PET images show larger discrepancies to the underlying microscopic reality which can be represented with an autoradiograph image. The differences between both images are caused by the lower resolution of PET images. This can also be very important when analyzing small tumour regions that exhibit low oxygen partial pressures. For tumours considered in this work this could also apply for the volumes that show an oxygen partial pressure of 2.5 mmHg. Therefore it can be concluded that higher resolution PET images are necessary to increase the feasibility of biological dose painting.

#### 6.1.2 Temporal variance

As seen in chapter 2.2.6, hypoxia can be categorized into chronic and acute hypoxia. Chronic hypoxia is a steady state, that does barely change on a larger time scale, while acute hypoxia exhibits larger fluctuations on the same time scale [7,96,102]. The largest problem with acute hypoxia for biological dose painting is that the hypoxic state of tumour volumes is derived from the PET intensity which is directly correlated to the retention of the hypoxia tracer. As biological dose painting should only target chronic hypoxia, the existence of acute hypoxia leads to an underestimation of the current oxygen partial pressure. This has a direct impact on the HRF distribution and dose escalations, as HRF will be higher in these regions. Of course, this fact only leads to an increased dose in this volume, which does not decrease tumour control but could lead to a scenario, where dose painting could not become feasible as OAR constraints limit the dose delivery. The Wang model [34] could enable biological dose painting to give an estimate on the fraction of acute hypoxia. For this approach two PET images are need in a specific time interval to evaluate the changes of oxygenation through FMISO.

#### 6.1.3 Reoxygenation & single image planning

When tumour cells are damage by ionizing radiation reoxygenation sets in as part of the repair process. This means, that multiple regions in the tumour could have a higher oxygen partial pressure, than assessed with the initial PET image which was used to create the treatment plan. Therefore, the dose requirements to achieve local tumour control with biological dose painting could be decreased by assessing reoxygenation by multiple PET images after a number of fractions. Ideally a new PET image should be the basis for every fraction, to assess tumour hypoxia in every step of the radiation treatment. This approach is not feasible in terms of dose (as PET imaging also introduces a dose to the patient) and treatment costs. As significant reoxygenation seems to be measurable after a certain amount of dose (cf. 3.1), it could be feasible to reassess the initial tumour map after each 10-15 fractions. This could improve the feasibility of dose painting, as hypoxia states are reevaluated and dose escalations are adapted to updated tumour environment.

#### 6.2 Interpretation of hypoxia

As seen in chapter 3.2.3, correlations between Eppendorf measurements and PET images have been investigated. Nevertheless, most studies have not been able to secure a clear relation between PET SUV and hypoxia for FMISO or other hypoxia tracers. It would be desirable to create a study to systematically investigate the real correlation of PET images and underlying oxygen partial pressures. This can help to understand with the interpretation of PET images and their implementation into the biological dose painting framework discussed in this work.

As discussed in chapter 6.1.1 PET images are not able to map the microenvironment with due regard to hypoxia. In a study conducted by *Petit et al.* [109] such microenvironmental influences on an intra-voxel basis were evaluated on a similar dose painting model as implemented in this work. The microenvironmental distribution of oxygen can lead to higher radioresistance as compared to homogeneous cellular pO2 distributions. This can lead to a median gain in cell kill when adapted to the biological dose painting approach of this work. One major drawback of a intra-voxel microenvironment distribution derived from PET is related to the changes introduces by reoxygenation of tumour volumes during radiotherapy. A closer investigation on the influence of intra-voxel distributions in terms of reoxygenation could help understand the complex approach of dynamic dose painting based on multiple PET images.

Chapter 7

Summary & Conclusions

## Appendix A

## Dose compensation for hypoxia

As hypoxia will decrease radio sensitivity the dose has to be increased to achieve the same biological effect. The reference effect is derived from the prescribed dose  $D_p$  with  $\varepsilon_p = \alpha_X D_p + \beta_X D_p^2$ . The compensating dose D to overcome the effects of hypoxia is

$$\underbrace{\alpha_X D_p + \beta_X D_p}_{=\varepsilon_p} \stackrel{!}{=} \frac{\alpha_X}{\text{HRF}} D + \frac{\beta_X}{\text{HRF}^2} D^2$$
(A.1)

Bringing this into a solvable quadratic form yields

$$\frac{\alpha_X}{\text{HRF}}D + \frac{\beta_X}{\text{HRF}^2}D^2 - \varepsilon_p = 0 \tag{A.2}$$

$$D^{2} + HRF \cdot \frac{\alpha_{X}}{\beta_{X}} \cdot D - \frac{HRF^{2}}{\beta_{X}} \varepsilon_{p} = 0.$$
 (A.3)

The two solutions to this equation are

$$D_{1,2} = \text{HRF}\left[-\frac{\alpha_X}{2\beta_X} \pm \sqrt{\left(\frac{\alpha_X}{2\beta_X}\right)^2 + \frac{\varepsilon_p}{\beta_X}}\right]$$
(A.4)

The negative solution is dropped as it generated a negative dose result and is therefore unphysical. Dose is linearly scaled up with the HRF to compensate for hypoxia and achieve the prescribed effect  $\varepsilon_p$ .

## Appendix B

## Patient statistics

All patients presented in this thesis have been provided with a clinical plan approved by a physician or radiation oncologist. All plans follow the HN06 trail dose constraints. Due to the incomparability of patients treatment volumes, every patient is presented with his own table.

		(a) Patient 1	1				(b) Patient 2	t 2	
Patient 1	Clinical	Clinical plan [Gy]	Biological	Biological dose painting [Gy]	Patient 1	Clinical	plan [Gy]	Biological	Biological dose painting [Gy]
Volume name	$D_{ m mean}$	$D_{\max}$	$D_{ m mean}$	$D_{ m max}$	Volume name	$D_{ m mean}$	$D_{\max}$	$D_{ m mean}$	$D_{\mathrm{max}}$
;						i			
DAAIN	19.10	70.10	12.02	10.00		10.47	40.00	60.21	42.00 6.10
BRSTEM	19.96	52.06	17.93	48.63	CHIASM	4.15	5.11	2.22	3.18
CHIASM	16.27	23.04	10.49	12.46	CORD	17.76	45.03	14.19	40.79
CORD	15.25	42.93	15.32	44.56	ESOPHAGUS	22.18	57.80	12.50	38.50
ESOPHAGUS	22.53	53.51	20.93	50.06	LARYNX	43.30	65.54	21.61	58.98
LARYNX	40.20	66.07	29.07	64.00	LEYE	2.42	5.51	1.60	3.00
TEYE	6.39	17.01	4.72	18.92	LIPS	16.05	39.85	11.21	26.67
$_{ m LIPS}$	17.94	50.01	26.72	41.30	LLENS	2.68	3.58	1.41	1.59
LLENS	5.29	6.52	3.60	4.80	LOPTIC	4.23	5.36	2.14	3.18
LNECK	40.62	77.64	50.90	115.46	LPLEXUS	29.85	72.07	25.65	64.10
LOPTIC	14.55	34.01	9.26	19.42	MANDIBLE	44.23	74.50	29.65	67.63
LPAROTID	38.62	74.63	65.8	85.5	POSTCRICOID	44.65	62.94	25.99	58.98
LPLEXUS	32.02	67.39	30.95	67.32	RACOUSTIC	28.84	55.83	11.73	29.14
MANDIBLE	42.03	75.01	39.40	74.74	REYE	2.12	4.59	1.59	2.47
POSTCRICOID	44.26	62.37	35.80	59.17	ROPTIC	3.77	4.79	1.92	2.65
REYE	5.59	11.73	4.68	14.38	RPAROTID	51.55	75.32	39.23	74.52
RLENS	4.39	5.78	4.10	6.95					
RNECK	39.67	77.33	50.32	89.11					
ROPTIC	10.60	17.71	8.55	11.74					
RPAROTID	34.53	75.19	34.26	77.37					
RPLEXUS	30.42	65.96	27.40	66.83					
CTV56	60.28	78.49	76.2	119.8	CTV56	68.59	76.32	71.20	88.30
CTV70	68.47	78.49	81.1	119.8	CTV70	71.27	76.32	74.60	88.30
$\operatorname{GTV}$	68.94	78.49	93.4	119.8	$\operatorname{GTV}$	72.19	76.32	81.90	88.30
GTV50	ı	1	95.5	119.8	GTV50	1	1	84.30	88.30
GTV25	ı	ı	92	119.8	GTV25	ı		ı	ı
PTV56	34.87	78.49	71.7	119.8	PTV56		76.32	06 40	88.30
PTV70	£1 E1	10 10				62.97		07.30	00.00

(b) Patient 2

$\mathfrak{S}$
Patient
´ပ`

Patient I         Clinical plan [Cy]         Biological dose painting [Cy]         Petient I         Clinical plan [Cy]         Biological dose painting [Cy]         Potition plan [Cy]         Potition plan [Cy]         Biological dose painting [Cy]           Volume name         D <sub>moson</sub> <t< th=""><th></th><th></th><th></th><th>)</th><th></th><th></th><th></th><th></th><th></th><th></th></t<>				)						
Dmean         Dmax         Dmean         Dmax         Volume name         Dmean         Dmean         Dmean         Dmean         Dmean           13 61         54.38         75.0         54.18         BRAIN         12.15         55.43         8.28           13 61         42.36         11.72         41.60         BRSTEM         14.96         59.21         10.63           2.75         3.18         21.72         41.60         BRSTEM         14.96         39.21         10.63           1.571         3.18         21.72         27.01         13.44         CORD         54.91         23.30           1.37         3.03         14.84         27.82         LARYNX         47.61         44.25           1.37         3.04         0.88         1.45         BRAROTID         23.06         63.33         22.50           4.09         1.32         1.45         A.76         A.76         44.125         31.21           1.37         2.03         4.60         75.90         A.76         75.10         25.05           4.09         1.38         4.60         75.90         A.76         75.32         31.21           2.13         3.24         1.38	Patient 1	Clinical	plan [Gy]	Biological c	lose painting [Gy]	Patient 1	Clinical	plan [Gy]	Biological	dose painting [Gy]
10.64         54.39         7.50         54.18         BRAIN         12.15         55.43         8.28           13.61         42.36         11.72         41.60         BRSTEM         14.96         39.21         10.63           2.75         3.18         2.11         3.14         CORD         15.91         38.47         13.85           15.71         38.51         12.36         37.01         ESOPHAGUS         26.20         54.91         13.85           1.34         4.05         1.08         2.04         LARWAN         47.51         44.25         43.00           1.37         2.034         1.484         27.82         LPAROTID         23.06         63.33         22.50           1.37         2.29         LAPRAN         47.57         74.76         44.25           2.93         3.348         1.75         A7.74         A7.74         47.57         44.25           4.094         76.24         33.48         74.74         A7.74         A7.74         47.74         47.74         47.74           2.03         4.14         1.14         1.94         A7.44         47.45         47.42         47.42         47.44         47.42         47.44 <td< th=""><th>Volume name</th><th><math>D_{\mathrm{mean}}</math></th><th><math>D_{ m max}</math></th><th>Dmean</th><th><math>D_{ m max}</math></th><th>Volume name</th><th><math>D_{ m mean}</math></th><th><math>D_{\max}</math></th><th><math>D_{ m mean}</math></th><th><math>D_{ m max}</math></th></td<>	Volume name	$D_{\mathrm{mean}}$	$D_{ m max}$	Dmean	$D_{ m max}$	Volume name	$D_{ m mean}$	$D_{\max}$	$D_{ m mean}$	$D_{ m max}$
13.61         42.36         11.72         41.60         BRSTEM         14.96         39.21         10.63           2.75         3.18         2.11         3.14         CORD         15.91         38.47         13.85           15.71         38.31         12.36         37.01         ESOPHARYNX         47.61         72.13         48.02           1.34         4.05         1.08         2.66         LARYNX         47.61         72.13         48.02           1.34         4.05         1.08         2.66         LAFRYNX         47.61         72.13         48.02           1.37         4.04         1.34         1.45         MANDIBLE         28.07         74.76         44.25           2.93         3.38         1.72         2.66         38.71         71.91         26.95           4.04         76.54         33.48         74.74         RPAROTID         28.07         77.12         31.21           2.03         3.10         1.14         1.94         RPAROTID         28.07         77.12         31.21           2.04         3.25         3.66         5.59         74.74         4.60         77.90         77.90         77.83         77.12         31	BRAIN	10.64	54.39	7.50	54.18	BRAIN	12.15	55.43	8.28	53.08
275         3.18         2.11         3.14         CORD         15.91         38.47         13.85           15.71         38.51         12.36         37.01         ESOPHAGUS         26.20         54.91         23.30           15.71         38.51         12.36         37.01         HYPOPHARYNX         47.57         74.76         44.25           1.34         1.08         2.66         LPAROTID         23.06         63.33         22.50           1.56         3.04         0.88         1.45         MANDIBLE         28.71         71.91         26.95           1.57         2.21         1.31         1.94         RPAROTID         26.03         72.12         31.21           2.03         66.56         25.91         63.85         74.74 <td< td=""><td><math>\operatorname{BRSTEM}</math></td><td>13.61</td><td>42.36</td><td>11.72</td><td>41.60</td><td>BRSTEM</td><td>14.96</td><td>39.21</td><td>10.63</td><td>33.06</td></td<>	$\operatorname{BRSTEM}$	13.61	42.36	11.72	41.60	BRSTEM	14.96	39.21	10.63	33.06
15.71         38.51         12.36         37.01         ESOPHAGUS         26.20         54.91         23.30           3.47.0         72.31         31.07         71.35         HYPOPHARYNX         47.61         72.13         48.02           1.34         4.05         2.66         LARNOTID         23.06         63.33         22.50           1.56         3.04         0.88         1.45         DANDIBLE         23.06         63.33         22.50           1.57         2.21         1.31         1.94         RPAROTID         26.03         72.12         31.21           2.93         3.38         1.72         2.66         MANDIBLE         28.71         71.91         26.95           4.0.94         76.24         2.591         63.85         72.12         31.21         31.21           2.0.92         3.10         1.14         1.94         RPAROTID         26.03         72.12         31.21           2.23         3.10         1.31         1.94         RPAROTID         26.03         72.12         31.21           2.24         4.60         75.90         4.60         4.60         4.60         4.60         4.60         4.60         4.60         4.60	$_{ m CHIASM}$	2.75	3.18	2.11	3.14	CORD	15.91	38.47	13.85	39.36
34.70         72.31         31.07         71.35         HYPOPHARYNX         47.61         72.13         48.02           1.34         4.05         1.08         2.66         LARYNX         47.57         74.76         44.25           1.37         30.34         14.84         27.82         LARYNX         47.57         74.76         44.25           1.57         30.34         14.84         27.82         LAFANDIBLE         28.71         71.91         26.95           1.27         2.21         1.31         1.94         RPAROTID         26.03         72.12         31.21           2.93         3.38         1.72         2.66         BANDIBLE         28.71         71.91         26.95           40.94         76.24         33.48         74.74         RPAROTID         26.03         72.12         31.21           26.93         1.38         1.47.44         1.44	CORD	15.71	38.51	12.36	37.01	ESOPHAGUS	26.20	54.91	23.30	50.61
1.34         4.05         1.08         2.66         LARYNX         47.57         74.76         44.25           1.37.2         30.34         14.84         27.82         LPAROTID         23.06         63.33         22.50           1.26         3.04         0.88         1.45         MANDIBLE         28.71         71.91         26.95           1.27         2.21         1.31         1.94         RPAROTID         26.03         72.12         31.21           2.93         3.38         1.72         2.66         8.77         71.91         26.95           40.94         76.24         33.48         74.74         8.60         72.12         31.21           2.93         4.60         76.59         74.74         1.94         72.13         74.74         74.74           2.22         3.10         1.14         1.94         1.94         75.46         75.46         75.46         75.46         75.46         75.40         75.40         75.40         75.40         75.40         75.40         75.40         75.40         75.40         75.40         75.40         75.40         75.40         75.40         75.40         75.40         75.40         75.40         75.40	ESOPHAGUS	34.70	72.31	31.07	71.35	HYPOPHARYNX	47.61	72.13	48.02	68.60
13.72         30.34         14.84         27.82         LPAROTID         23.06         63.33         22.50           1.26         3.04         0.88         1.45         MANDIBLE         28.71         71.91         26.95           2.93         3.38         1.72         2.66         33.48         74.74         26.93         72.12         31.21           2.93         66.56         25.91         63.85         74.74         26.93         72.12         31.21           2.0.3         76.34         76.50         75.90         75.90         75.90         72.13         72.12         31.21           2.0.2         3.10         1.14         1.94         76.84         76.84         76.84         76.84           2.22         3.10         1.31         1.94         75.46         75.46         75.46         75.46         75.46         75.46         75.46         75.40         76.85         74.40           29.89         72.13         31.46         72.32         76.78         76.78         80.00           71.12         76.47         88.90         120.90         CTV70         68.50         76.78         80.00           -         -         -	LEYE	1.34	4.05	1.08	2.66	LARYNX	47.57	74.76	44.25	68.37
1.56         3.04         0.88         1.45         MANDIBLE         28.71         71.91         26.95           1.27         2.21         1.34         RPAROTID         26.03         72.12         31.21           2.93         3.38         74.74         RPAROTID         26.03         72.12         31.21           26.93         76.24         33.48         74.74         75.90         72.12         31.21           26.93         66.56         25.91         63.85         66.56         25.91         63.85           3.443         73.87         47.60         75.90         75.90         75.90         75.90           2.22         3.10         1.14         1.94         75.46         75.46         75.46           3.13         3.64         2.28         2.90         75.46         75.46         76.85         74.40           43.82         75.24         40.46         75.46         75.46         76.85         74.40           60.55         76.54         77.90         120.90         77.89         76.78         80.00           71.12         76.47         88.90         120.90         77.79         76.85         77.40           - </td <td>LIPS</td> <td>13.72</td> <td>30.34</td> <td>14.84</td> <td>27.82</td> <td>LPAROTID</td> <td>23.06</td> <td>63.33</td> <td>22.50</td> <td>58.48</td>	LIPS	13.72	30.34	14.84	27.82	LPAROTID	23.06	63.33	22.50	58.48
1.27       2.21       1.31       1.94       RPAROTID       26.03       72.12       31.21         2.93       3.38       1.72       2.66       8.34       74.74       8.348       74.74       8.348       74.74       8.348       74.74       8.348       74.74       8.35       8.35       8.35       8.321	LLACRIMAL	1.56	3.04	0.88	1.45	MANDIBLE	28.71	71.91	26.95	70.85
2.93       3.38       1.72       2.66         40.94       76.24       33.48       74.74         26.93       66.56       25.91       63.85         34.43       73.87       47.60       75.90         2.13       66.59       1.32       4.60         2.02       3.10       1.14       1.94         2.22       3.10       1.31       1.94         3.13       3.64       2.28       2.90         43.82       75.24       40.46       75.46         29.89       75.13       31.46       75.32         60.55       76.52       81.60       120.90       CTV70       68.50       76.85       74.40         71.12       76.47       88.90       120.90       CTV70       68.50       76.85       74.40         71.12       76.47       88.90       120.90       CTV70       63.50       76.78       80.00         -       -       94.40       120.90       CTV50       67.02       -       -       96.80         -       -       104.60       120.90       CTV50       65.40       76.85       67.70         36.08       76.94       76.09       76.	LLENS	1.27	2.21	1.31	1.94	RPAROTID	26.03	72.12	31.21	68.37
40.94         76.24         33.48         74.74           26.93         66.56         25.91         63.85           34.43         73.87         47.60         75.90           2.13         6.99         1.32         4.60           2.02         3.10         1.14         1.94           2.22         3.10         1.31         1.94           3.13         3.64         2.28         2.90           43.82         75.24         40.46         75.46           29.89         72.13         31.46         72.32           60.55         76.54         77.90         120.90           60.56         76.52         81.60         120.90           71.12         76.47         88.90         120.90           71.12         76.47         88.90         120.90           71.12         76.47         76.78           85.00         76.78         80.00           -         -         94.40         120.90           -         -         94.40         120.90           -         -         94.40         120.90           -         -         -           -         -	LOPTIC	2.93	3.38	1.72	2.66					
26.93         66.56         25.91         63.85           34.43         73.87         47.60         75.90           2.02         3.10         1.14         1.94           2.22         3.10         1.31         1.94           3.13         3.64         2.28         2.90           43.82         75.24         40.46         75.46           59.89         72.13         31.46         72.32           60.55         76.94         77.90         120.90         CTV70         66.48         76.85         71.60           69.96         76.52         81.60         120.90         CTV70         68.50         76.78         80.00           71.12         76.47         88.90         120.90         CTV70         68.50         76.78         80.00           -         -         94.40         120.90         CTV70         67.78         80.00           -         -         94.40         120.90         CTV70         68.50         76.85         67.70           -         -         94.40         120.90         CTV70         68.50         -         -         96.80           -         -         -         -	LPAROTID	40.94	76.24	33.48	74.74					
34.43       73.87       47.60       75.90         2.13       6.99       1.32       4.60         2.02       3.10       1.14       1.94         2.22       3.10       1.13       1.94         3.13       3.64       2.28       2.90         43.82       75.24       40.46       75.46         59.89       72.13       31.46       72.32         60.55       76.54       77.90       120.90       CTV76       66.48       76.85       74.40         69.96       76.52       81.60       120.90       CTV70       68.50       76.78       80.00         71.12       76.47       88.90       120.90       GTV       71.39       76.78       80.00         -       -       94.40       120.90       GTV       71.39       76.78       80.00         -       -       104.60       120.90       GTV       71.29       66.80       76.85       67.70         -       -       104.60       120.90       GTV       76.85       67.70         -       -       104.60       120.90       GTV       76.85       67.70         -       -       -       - </td <td><math>\Gamma</math></td> <td>26.93</td> <td>66.56</td> <td>25.91</td> <td>63.85</td> <td></td> <td></td> <td></td> <td></td> <td></td>	$\Gamma$	26.93	66.56	25.91	63.85					
2.13       6.99       1.32       4.60         2.22       3.10       1.14       1.94         3.13       3.64       2.28       2.90         43.82       75.24       40.46       75.46         29.89       72.13       31.46       72.32         60.55       76.94       77.90       120.90       CTV76       66.48       76.85       74.40         69.96       76.52       81.60       120.90       CTV70       68.50       76.85       74.40         71.12       76.47       88.90       120.90       CTV70       68.50       76.78       80.00         71.12       76.47       88.90       120.90       CTV70       68.50       76.78       80.00         71.12       76.47       88.90       120.90       CTV70       68.50       76.78       80.00         76.94       76.94       76.90       120.90       PTV76       65.40       76.85       67.70         36.08       76.94       76.94       76.85       67.70       71.20	MANDIBLE	34.43	73.87	47.60	75.90					
2.22       3.10       1.14       1.94         2.22       3.10       1.31       1.94         3.13       3.64       2.28       2.90         43.82       75.24       40.46       75.46         29.89       72.13       31.46       72.32         60.55       76.94       77.90       120.90       CTV76       66.48       76.85       71.60         69.96       76.52       81.60       120.90       CTV70       68.50       76.85       74.40         71.12       76.47       88.90       120.90       CTV70       68.50       76.78       80.00         71.12       76.47       88.90       120.90       CTV70       68.50       76.78       80.00         71.12       76.47       88.90       120.90       CTV70       67.07       76.78       80.00         71.12       76.47       76.68       76.78       66.80       76.85       67.70         70.50       76.94       76.85       67.70       71.20       71.20	REYE	2.13	6.99	1.32	4.60					
2.22       3.10       1.31       1.94         3.13       3.64       2.28       2.90         5       43.82       75.24       40.46       75.46         60.55       76.94       77.90       120.90       CTV56       66.48       76.85       71.60         69.96       76.52       81.60       120.90       CTV70       68.50       76.85       74.40         71.12       76.47       88.90       120.90       CTV70       68.50       76.85       74.40         -       -       94.40       120.90       CTV50       67V       71.39       76.78       80.00         -       -       104.60       120.90       CTV50       67.70       -       96.80         -       -       104.60       120.90       PTV56       59.00       76.85       67.70         36.08       76.94       76.90       120.90       PTV70       65.40       76.85       67.70	RLACRIMAL	2.02	3.10	1.14	1.94					
3.13       3.64       2.28       2.90         43.82       75.24       40.46       75.46         60.55       76.94       77.90       120.90       CTV76       66.48       76.85       71.60         69.96       76.52       81.60       120.90       CTV70       68.50       76.85       74.40         71.12       76.47       88.90       120.90       CTV70       68.50       76.78       80.00         -       -       94.40       120.90       CTV50       -       -       86.00         -       -       104.60       120.90       CTV56       65.90       76.85       67.70         35.33       76.94       76.90       120.90       PTV56       59.00       76.85       67.70         36.08       76.94       76.90       120.90       PTV70       65.40       76.85       67.70	RLENS	2.22	3.10	1.31	1.94					
5       43.82       75.24       40.46       75.46         5       29.89       72.13       31.46       72.32         60.55       76.94       77.90       120.90       CTV 76       66.48       76.85       71.60         69.96       76.52       81.60       120.90       CTV 70       68.50       76.85       74.40         71.12       76.47       88.90       120.90       CTV 70       68.50       76.78       80.00         -       -       94.40       120.90       CTV 50       -       -       86.00         -       -       104.60       120.90       PTV 56       59.00       76.85       67.70         35.33       76.94       76.90       120.90       PTV 70       65.40       76.85       67.70	ROPTIC	3.13	3.64	2.28	2.90					
29.89         72.13         31.46         72.32           60.55         76.94         77.90         120.90         CTV56         66.48         76.85         71.60           69.96         76.52         81.60         120.90         CTV70         68.50         76.85         74.40           71.12         76.47         88.90         120.90         CTV7         68.50         76.85         74.40           -         -         94.40         120.90         GTV5         -         -         86.00           -         -         104.60         120.90         GTV25         -         -         96.80           35.33         76.94         76.90         120.90         PTV56         59.00         76.85         67.70           36.08         76.94         76.90         120.90         PTV70         65.40         76.85         71.20	RPAROTID	43.82	75.24	40.46	75.46					
60.55         76.94         77.90         120.90         CTV56         66.48         76.85         71.60           69.96         76.52         81.60         120.90         CTV70         68.50         76.85         74.40           71.12         76.47         88.90         120.90         GTV         71.39         76.78         80.00           -         94.40         120.90         GTV         -         -         86.00           -         104.60         120.90         GTV         -         96.80           35.33         76.94         76.94         76.85         67.70           36.08         76.94         76.90         76.85         71.20	RPLEXUS	29.89	72.13	31.46	72.32					
69.96 76.52 81.60 120.90 CTV70 68.50 76.85 74.40 71.12 76.47 88.90 120.90 CTV70 68.50 76.78 80.00 94.40 120.90 CTV25 - 86.00 104.60 120.90 PTV56 59.00 76.85 67.70 36.08 76.94 76.90 120.90 PTV70 65.40 76.85 71.20	CTVER	80 87	76 04	00 22	130 90	AZVTP.	86.48	76.85	71 60	119 50
09.30         70.47         88.90         120.90         CTV         71.39         76.78         80.00           71.12         76.47         88.90         120.90         CTV50         -         -         86.00           -         -         104.60         120.90         CTV25         -         96.80           35.33         76.94         72.60         120.90         PTV56         59.00         76.85         67.70           36.08         76.94         76.90         120.90         PTV70         65.40         76.85         71.20	OT1770	90.09	76.53	01.50	130.00		60 EO	76.05	74.40	110 60
- 94.40 120.90 GTV50 - 86.00 104.60 120.90 GTV25 - 96.80 35.33 76.94 72.60 120.90 PTV56 59.00 76.85 67.70 36.08 76.94 76.90 120.90 PTV70 65.40 76.85 71.20		09.90	10.02	00.18	120.30		71 20	76.79	80.00	119.50
104.60 120.90 GTV25 96.80 104.60 120.90 GTV25 - 96.80 35.33 76.94 72.60 120.90 PTV56 59.00 76.85 67.70 36.08 76.94 76.90 120.90 PTV70 65.40 76.85 71.20	A TO	71:17	F-0-	04.30	150.50		00:11		00.00	119 50
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	00 1 15	ı	ı	94.40	120.30	067.15	ı	ı	00.00	00.211
35.33 76.94 72.60 120.90 PTV56 59.00 76.85 67.70 36.08 76.94 76.90 120.90 PTV70 65.40 76.85 71.20	GTV25	ı	ı	104.60	120.90	GTV25	ı	1	96.80	112.50
36.08 $76.94$ $76.90$ $120.90$ PTV70 $65.40$ $76.85$ $71.20$	PTV56	35.33	76.94	72.60	120.90	PTV56	59.00	76.85	67.70	112.50
	PTV70	36.08	76.94	06.92	120.90	PTV70	65.40	76.85	71.20	112.50

Patient 1 Volume name	Clinical $D_{\mathrm{mean}}$	(e) Patient 5  Clinical plan [Gy] $D_{\text{mean}}$	$t 5$ $Biological$ $D_{mean}$	$egin{array}{cccccccccccccccccccccccccccccccccccc$		Patient 1 Volume name		$\begin{array}{c} & \text{(f)} \\ \hline & \text{Clinical plan} \\ \hline & D_{\text{mean}} & I \end{array}$	
VOIGILIO HOULD	Dmean	₽ max	r mean	Umax	1	A CTUTIFIC HOTHER		Emean	L'mean L'max
BRSTEM	16.65	49.23	11.74	44.75		BRSTEM	BRSTEM 29.12		29.12
CHIASM	3.09	3.58	2.11	3.03		CHIASM		30.59	30.59   51.82
CORD	17.83	43.31	14.97	44.05		CORD		17.23	17.23 41.62
ESOPHAGUS	25.75	58.55	18.65	55.24		ESOPHAGUS		35.76	35.76 74.35
LARYNX	50.06	71.77	38.94	68.76		LACOUSTIC	LACOUSTIC 34.22	34.22	34.22   50.04
TEYE	2.32	6.27	1.48	3.73 50 81		LARYNX			46.62   74.23   3   75.3
LLACRIMAL	2.37	2.91	1.24	1.87		LIPS	LIPS 14.50	$\frac{2:87}{14.50}$	$\frac{2:87}{14.50}$
LLENS	2.56	3.33	1.45	1.87		LLACRIMAL		3.06	3.06   4.75
LNECK	57.64	75.84	52.04	75.52		LLENS		3.29	3.29   3.91
LOPTIC	3.54 33 30	4.19 75 74	2.20	3.50		LOPTIC	LOPTIC 17.92		17.92
LPHARYNGEAL	62.12	72.91	52.79	72.02		MANDIBLE		44.60	44.60 73.74
MANDIBLE	37.41	74.39	38.08	75.05		POSTCRICOID		51.11	51.11 75.17
RLACRIMAL	2.81	3.67	$\frac{1.62}{1.62}$	2.33		REYE	REYE 4.55		4.55 $15.51$
RLENS	2.99	3.66	1.80	2.56		RLACRIMAL		4.50	4.50 8.95
RNECK	54.13	76.20	44.39	82.51		RLENS		3.94	3.94 5.01
RPAROTID	29.44	73.20	34.81	67.36		RPAROTID	RPAROTID 46.79		46.79
RPHARYNGEAL	61.55	73.29	50.33	75.75					
CTV56	42.57	77.35	73.00	116.60		CTV56	CTV56 41.55	41.55	41.55
CTV70	46.45	77.35	76.60	116.60		CTV70			60.76 78.02
GTV50	69.81	77.00	85.50			GTV	GTV25 53.50	63.50	63.50
$\mathrm{GTV}25$	1		91.20	116.60		$\mathrm{GTV25}$		ı	1
PTV56 $PTV70$	35.30	1	91.20 100.70	116.60 116.60		GTV25 $GTV50$		1	

(f) Patient 4

## **Bibliography**

- [1] K. Bethge, G. Walter, and B. Wiedemann. Kernphysik. Springer, 2006.
- [2] W Jauch and R. Rohrlich. The theory of photons and electrons. Springer, 1976.
- [3] W Heitler. The quantum field theory of radiation. Dover, 1954.
- [4] W. Leo. Techniques for nuclear and particle physics experiments. Springer, 1987.
- [5] Tikvah Alper. Cellular radiobiology. Cambridge, 1979.
- [6] E. J. Hall and A. J. Giaccia. Radiobiology for the radiologist. *Lippincott Williams & Wilkins*, 2005.
- [7] R. K. Sachs, P. Hahnfeld, and D. J. Brenner. The link between low-LET dose-response relations and the underlying kinetics of damage production/repair/misrepair. *Int. J. Radiat. Biol.*, 72:351– 374, Oct 1997.
- [8] A. K. Cronqvist. Quantification of the response of heterogeneous tumours and organized normal tissues to fractionated radiotherapy. PhD thesis, Stockholm University, Stockholm, 1995.
- [9] A. Eisbruch, R. K. Ten Haken, H. M. Kim, L. H. Marsh, and J. A. Ship. Dose, volume, and function relationships in parotid salivary glands following conformal and intensity-modulated irradiation of head and neck cancer. *Int. J. Radiat. Oncol. Biol. Phys.*, 45:577–587, Oct 1999.
- [10] H. B. Honore, S. M. Bentzen, K. Mueller, and C. Grau. Sensori-neural hearing loss after radiotherapy for nasopharyngeal carcinoma: individualized risk estimation. *Radiother Oncol*, 65:9–16, Oct 2002.
- [11] J. M. Roesink, M. A. Moerland, J. J. Battermann, G. J. Hordijk, and C. H. Terhaard. Quantitative dose-volume response analysis of changes in parotid gland function after radiotherapy in the headand-neck region. *Int. J. Radiat. Oncol. Biol. Phys.*, 51:938–946, Nov 2001.
- [12] T. E. Schultheiss. The radiation dose-response of the human spinal cord. Int. J. Radiat. Oncol. Biol. Phys., 71:1455–1459, Aug 2008.
- [13] H. R. Withers, L. J. Peters, and J. M. Taylor. Dose-response relationship for radiation therapy of subclinical disease. *Int. J. Radiat. Oncol. Biol. Phys.*, 31:353–359, Jan 1995.
- [14] D. J. Carlson, R. D. Stewart, V. A. Semenenko, and G. A. Sandison. Combined use of Monte Carlo DNA damage simulations and deterministic repair models to examine putative mechanisms of cell killing. *Radiat. Res.*, 169:447–459, Apr 2008.

viii BIBLIOGRAPHY

[15] Y. Furusawa, K. Fukutsu, M. Aoki, H. Itsukaichi, K. Eguchi-Kasai, H. Ohara, F. Yatagai, T. Kanai, and K. Ando. Inactivation of aerobic and hypoxic cells from three different cell lines by accelerated (3)He-, (12)C- and (20)Ne-ion beams. *Radiat. Res.*, 154:485–496, Nov 2000.

- [16] M. Kramer and M. Scholz. Treatment planning for heavy-ion radiotherapy: calculation and optimization of biologically effective dose. *Phys Med Biol*, 45:3319–3330, Nov 2000.
- [17] M. Stuschke and H. D. Thames. Fractionation sensitivities and dose-control relations of head and neck carcinomas: analysis of the randomized hyperfractionation trials. *Radiother Oncol*, 51:113–121, May 1999.
- [18] E. Petry. Zur Kenntnis der Bedingungen der biologischen Wirkung der Röntgenstrahlen. Biochem. Zeitschr., 135:353, 1923.
- [19] J. C. Mottram. Factor of importance in radiosensitivity of tumours. Brit. J. Radiol., 9:606-614, 1936.
- [20] L. H. Gray, A. D. Conger, M. Ebert, S. Hornsey, and O. C. Scott. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol, 26:638–648, Dec 1953.
- [21] J. P. Kirkpatrick, L. I. Cardenas-Navia, and M. W. Dewhirst. Predicting the effect of temporal variations in PO2 on tumor radiosensitivity. *Int. J. Radiat. Oncol. Biol. Phys.*, 59:822–833, Jul 2004.
- [22] G. L. Semenza. Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer, 3:721-732, Oct 2003.
- [23] M. C. Simon. Diverse effects of hypoxia on tumor progression. Springer, 2010.
- [24] D. J. Carlson, R. D. Stewart, and V. A. Semenenko. Effects of oxygen on intrinsic radiation sensitivity: A test of the relationship between aerobic and hypoxic linear-quadratic (LQ) model parameters. *Med Phys*, 33:3105–3115, Sep 2006.
- [25] D. J. Carlson, P. J. Keall, B. W. Loo, Z. J. Chen, and J. M. Brown. Hypofractionation results in reduced tumor cell kill compared to conventional fractionation for tumors with regions of hypoxia. *Int. J. Radiat. Oncol. Biol. Phys.*, 79:1188–1195, Mar 2011.
- [26] I. Toma-Dasu, J. Uhrdin, L. Antonovic, A. Dasu, S. Nuyts, P. Dirix, K. Haustermans, and A. Brahme. Dose prescription and treatment planning based on FMISO-PET hypoxia. Acta Oncol, Aug 2011.
- [27] I. F. Tannock. Oxygen diffusion and the distribution of cellular radiosensitivity in tumours. Br J Radiol, 45:515–524, Jul 1972.
- [28] C. C. Ling, H. B. Michaels, E. R. Epp, and E. C. Peterson. Interaction of misonidazole and oxygen in the radiosensitization of mammalian cells. *Int. J. Radiat. Oncol. Biol. Phys.*, 6:583–589, May 198.
- [29] C. J. Koch, C. C. Stobbe, and E. A. Bump. The effect on the Km for radiosensitization at 0 degree C of thiol depletion by diethylmaleate pretreatment: quantitative differences found using the radiation sensitizing agent misonidazole or oxygen. *Radiat. Res.*, 98:141–153, Apr 1984.

BIBLIOGRAPHY ix

[30] D. W. Whillans and J. W. Hunt. A Rapid-Mixing Comparison of the Mechanisms of Radiosensitization by Oxygen and Misonidazole in CHO Cells. Rad. Res., 90-1:126-141, Apr 1982.

- [31] B. Cullen and I. Lansley. The effect of pre-irradiation growth conditions on the relative radiosensitivities of mammalian cells at low oxygen concentrations. Int. J. Radiat. Biol. Relat. Stud. Phys. Chem. Med., 26:579–588, Dec 1974.
- [32] B. Cullen and T. B. Constable. Independence of the radiobiological oxygen constant, K, and the respiration rate of mammalian cells. Int. J. Radiat. Biol. Relat. Stud. Phys. Chem. Med., 29:343–350, Apr 1976.
- [33] B. G. Wouters and J. M. Brown. Cells at intermediate oxygen levels can be more important than the "hypoxic fraction" in determining tumor response to fractionated radiotherapy. *Radiat. Res.*, 147:541–550, May 1997.
- [34] K. Wang, E. Yorke, S. A. Nehmeh, J. L. Humm, and C. C. Ling. Modeling acute and chronic hypoxia using serial images of 18F-FMISO PET. Med Phys, 36:4400–4408, Oct 2009.
- [35] A. Brahme, J. E. Roos, and I. Lax. Solution of an integral equation encountered in rotation therapy. Phys Med Biol, 27:1221–1229, Oct 1982.
- [36] S. Webb. Optimization of conformal radiotherapy dose distributions by simulated annealing. Phys Med Biol, 34:1349–1370, Oct 1989.
- [37] T. Bortfeld, J. Burkelbach, R. Boesecke, and W. Schlegel. Methods of image reconstruction from projections applied to conformation radiotherapy. *Phys Med Biol*, 35:1423–1434, Oct 1990.
- [38] D J Convery and M E Rosenbloom. The generation of intensity-modulated fields for conformal radiotherapy by dynamic collimation. *Phys. Med. Biol.*, 37:1359–1374, 1992.
- [39] C. C. Ling, C. Burman, C. S. Chui, G. J. Kutcher, S. A. Leibel, T. LoSasso, R. Mohan, T. Bortfeld, L. Reinstein, S. Spirou, X. H. Wang, Q. Wu, M. Zelefsky, and Z. Fuks. Conformal radiation treatment of prostate cancer using inversely-planned intensity-modulated photon beams produced with dynamic multileaf collimation. *Int. J. Radiat. Oncol. Biol. Phys.*, 35:721–730, Jul 1996.
- [40] A. Lomax. Intensity modulation methods for proton radiotherapy. Phys Med Biol, 44:185–205, Jan 1999.
- [41] S Nill. Development and application of a multimodality inverse treament planning system.

  Medical Physics, 29(2):258, 2002.
- [42] J. J. Wilkens and U. Oelfke. Fast multifield optimization of the biological effect in ion therapy. Phys Med Biol, 51:3127–3140, Jun 2006.
- [43] J. J. Wilkens and U. Oelfke. A phenomenological model for the relative biological effectiveness in therapeutic proton beams. *Phys Med Biol*, 49:2811–2825, Jul 2004.
- [44] J. J. Wilkens and U. Oelfke. Optimization of radiobiological effects in intensity modulated proton therapy. Med Phys, 32:455–465, Feb 2005.
- [45] R H Byrd, P Lu, J Nocedal, and C Zhu. A limited-memory algorithm for bound constrained optimization. SIAM Journal on Scientific Computing, 16:1190–1208, 1994.

x BIBLIOGRAPHY

[46] U. Oelfke and T. Bortfeld. Inverse planning for photon and proton beams. Med Dosim, 26:113–124, 2001.

- [47] M. Zaider and H. H. Rossi. The synergistic effects of different radiations. Radiat. Res., 83:732–739, Sep 1980.
- [48] M. C. Frese. Potentials and Risks of Advanced Radiobiological Treatment Planning for Proton and Carbon Ion Therapy. PhD thesis, University of Heidelberg, Heidelberg, 2011.
- [49] K. Nakamura and others (Particle Data Group). Review of Particle Physics. Journal of Physics G37, 2011.
- [50] G. Musiol, J. Ranft, R. Reif, et al. Kern- und elementarteilchenphysik. VCH, 1985.
- [51] S. Cherry and M. Dahlborn. Pet: Physics instrumentation and scanners. Springer, 2006.
- [52] K. R. Zasadny and R. L. Wahl. Standardized uptake values of normal tissues at PET with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose: variations with body weight and a method for correction. *Radiology*, 189:847–850, Dec 1993.
- [53] C. K. Kim, N. C. Gupta, B. Chandramouli, and A. Alavi. Standardized uptake values of FDG: body surface area correction is preferable to body weight correction. *J. Nucl. Med.*, 35:164–167, Jan 1994.
- [54] K. A. Krohn, J. M. Link, and R. P. Mason. Molecular imaging of hypoxia. J. Nucl. Med., 49 Suppl 2:129S-48S, Jun 2008.
- [55] M. Busk, M. R. Horsman, S. Jakobsen, J. Bussink, A. van der Kogel, and J. Overgaard. Cellular uptake of PET tracers of glucose metabolism and hypoxia and their linkage. *Eur. J. Nucl. Med. Mol. Imaging*, 35:2294–2303, Dec 2008.
- [56] J. Oswald, F. Treite, C. Haase, T. Kampfrath, P. Mading, B. Schwenzer, R. Bergmann, and J. Pietzsch. Experimental hypoxia is a potent stimulus for radiotracer uptake in vitro: comparison of different tumor cells and primary endothelial cells. *Cancer Lett.*, 254:102–110, Aug 2007.
- [57] J. L. Dearling, J. S. Lewis, G. E. Mullen, M. T. Rae, J. Zweit, and P. J. Blower. Design of hypoxia-targeting radiopharmaceuticals: selective uptake of copper-64 complexes in hypoxic cells in vitro. Eur J Nucl Med, 25:788-792, Jul 1998.
- [58] H. Yuan, T. Schroeder, J. E. Bowsher, L. W. Hedlund, T. Wong, and M. W. Dewhirst. Intertumoral differences in hypoxia selectivity of the PET imaging agent 64Cu(II)-diacetyl-bis(N4methylthiosemicarbazone). J. Nucl. Med., 47:989–998, Jun 2006.
- [59] A. Obata, M. Yoshimoto, S. Kasamatsu, H. Naiki, S. Takamatsu, K. Kashikura, T. Furukawa, J. S. Lewis, M. J. Welch, H. Saji, Y. Yonekura, and Y. Fujibayashi. Intra-tumoral distribution of (64)Cu-ATSM: a comparison study with FDG. *Nucl. Med. Biol.*, 30:529–534, Jul 2003.
- [60] D. Sorger, M. Patt, P. Kumar, L. I. Wiebe, H. Barthel, A. Seese, C. Dannenberg, A. Tannapfel, R. Kluge, and O. Sabri. [18F]Fluoroazomycinarabinofuranoside (18FAZA) and [18F]Fluoromisonidazole (18FMISO): a comparative study of their selective uptake in hypoxic cells and PET imaging in experimental rat tumors. Nucl. Med. Biol., 30:317–326, Apr 2003.

BIBLIOGRAPHY xi

[61] M. Busk, M. R. Horsman, S. Jakobsen, S. Keiding, A. J. van der Kogel, J. Bussink, and J. Overgaard. Imaging hypoxia in xenografted and murine tumors with 18F-fluoroazomycin arabinoside: a comparative study involving microPET, autoradiography, PO2-polarography, and fluorescence microscopy. *Int. J. Radiat. Oncol. Biol. Phys.*, 70:1202–1212, Mar 2008. [DOI:10.1016/j.ijrobp.2007.11.034] [PubMed:18313528].

- [62] H. Barthel, H. Wilson, D. R. Collingridge, G. Brown, S. Osman, S. K. Luthra, F. Brady, P. Workman, P. M. Price, and E. O. Aboagye. In vivo evaluation of [18F] fluoroetanidazole as a new marker for imaging tumour hypoxia with positron emission tomography. Br. J. Cancer, 90:2232–2242, Jun 2004.
- [63] D. J. Yang, S. Wallace, A. Cherif, C. Li, M. B. Gretzer, E. E. Kim, and D. A. Podoloff. Development of F-18-labeled fluoroerythronitroimidazole as a PET agent for imaging tumor hypoxia. *Radiology*, 194:795–800, Mar 1995.
- [64] T. Gronroos, L. Bentzen, P. Marjamaki, R. Murata, M. R. Horsman, S. Keiding, O. Eskola, M. Haaparanta, H. Minn, and O. Solin. Comparison of the biodistribution of two hypoxia markers [18F]FETNIM and [18F]FMISO in an experimental mammary carcinoma. Eur. J. Nucl. Med. Mol. Imaging, 31:513–520, Apr 2004.
- [65] S. M. Evans, A. V. Kachur, C. Y. Shiue, R. Hustinx, W. T. Jenkins, G. G. Shive, J. S. Karp, A. Alavi, E. M. Lord, W. R. Dolbier, and C. J. Koch. Noninvasive detection of tumor hypoxia using the 2-nitroimidazole [18F]EF1. J. Nucl. Med., 41:327–336, Feb 2000.
- [66] N. Christian, A. Bol, M. De Bast, D. Labar, J. Lee, P. Mahy, and V. Gregoire. Determination of tumour hypoxia with the PET tracer [18F]EF3: improvement of the tumour-to-background ratio in a mouse tumour model. *Eur. J. Nucl. Med. Mol. Imaging*, 34:1348–1354, Sep 2007.
- [67] L. S. Ziemer, S. M. Evans, A. V. Kachur, A. L. Shuman, C. A. Cardi, W. T. Jenkins, J. S. Karp, A. Alavi, W. R. Dolbier, and C. J. Koch. Noninvasive imaging of tumor hypoxia in rats using the 2-nitroimidazole 18F-EF5. Eur. J. Nucl. Med. Mol. Imaging, 30:259–266, Feb 2003.
- [68] G. Komar, M. Seppanen, O. Eskola, P. Lindholm, T. J. Gronroos, S. Forsback, H. Sipila, S. M. Evans, O. Solin, and H. Minn. 18F-EF5: a new PET tracer for imaging hypoxia in head and neck cancer. J. Nucl. Med., 49:1944–1951, Dec 2008.
- [69] J. Chang, B. Wen, P. Kazanzides, P. Zanzonico, R. D. Finn, G. Fichtinger, and C. C. Ling. A robotic system for 18F-FMISO PET-guided intratumoral pO2 measurements. *Med Phys*, 36:5301– 5309, Nov 2009.
- [70] S. R. Bowen, A. J. van der Kogel, M. Nordsmark, S. M. Bentzen, and R. Jeraj. Characterization of positron emission tomography hypoxia tracer uptake and tissue oxygenation via electrochemical modeling. *Nucl. Med. Biol.*, 38:771–780, Aug 2011.
- [71] M. Piert, H. J. Machulla, G. Becker, P. Aldinger, E. Winter, and R. Bares. Dependency of the [18F]fluoromisonidazole uptake on oxygen delivery and tissue oxygenation in the porcine liver. *Nucl. Med. Biol.*, 27:693–700, Nov 2000.

xii BIBLIOGRAPHY

[72] N. Lawrentschuk, A. M. Poon, S. S. Foo, L. G. Putra, C. Murone, I. D. Davis, D. M. Bolton, and A. M. Scott. Assessing regional hypoxia in human renal tumours using 18F-fluoromisonidazole positron emission tomography. *BJU Int.*, 96:540–546, Sep 2005.

- [73] M. Zimny, B. Gagel, E. DiMartino, K. Hamacher, H. H. Coenen, M. Westhofen, M. Eble, U. Buell, and P. Reinartz. FDG—a marker of tumour hypoxia? A comparison with [18F]fluoromisonidazole and pO2-polarography in metastatic head and neck cancer. Eur. J. Nucl. Med. Mol. Imaging, 33:1426–1431, Dec 2006.
- [74] B. Gagel, M. Piroth, M. Pinkawa, P. Reinartz, M. Zimny, H. J. Kaiser, S. Stanzel, B. Asadpour, C. Demirel, K. Hamacher, H. H. Coenen, T. Scholbach, P. Maneschi, E. DiMartino, and M. J. Eble. pO polarography, contrast enhanced color duplex sonography (CDS), [18F] fluoromisonidazole and [18F] fluorodeoxyglucose positron emission tomography: validated methods for the evaluation of therapy-relevant tumor oxygenation or only bricks in the puzzle of tumor hypoxia? BMC Cancer, 7:113, 2007.
- [75] B. Gagel, P. Reinartz, E. Dimartino, M. Zimny, M. Pinkawa, P. Maneschi, S. Stanzel, K. Hamacher, H. H. Coenen, M. Westhofen, U. Bull, and M. J. Eble. pO(2) Polarography versus positron emission tomography ([(18)F] fluoromisonidazole, [(18)F]-2-fluoro-2'-deoxyglucose). An appraisal of radiotherapeutically relevant hypoxia. Strahlenther Onkol, 180:616–622, Oct 2004.
- [76] J. S. Rasey, W. J. Koh, M. L. Evans, L. M. Peterson, T. K. Lewellen, M. M. Graham, and K. A. Krohn. Quantifying regional hypoxia in human tumors with positron emission tomography of [18F]fluoromisonidazole: a pretherapy study of 37 patients. *Int. J. Radiat. Oncol. Biol. Phys.*, 36:417–428, Sep 1996.
- [77] L. Bentzen, S. Keiding, M. Nordsmark, L. Falborg, S. B. Hansen, J. Keller, O. S. Nielsen, and J. Overgaard. Tumour oxygenation assessed by 18F-fluoromisonidazole PET and polarographic needle electrodes in human soft tissue tumours. *Radiother Oncol*, 67:339–344, Jun 2003.
- [78] L. S. Mortensen, S. Buus, M. Nordsmark, L. Bentzen, O. L. Munk, S. Keiding, and J. Overgaard. Identifying hypoxia in human tumors: A correlation study between 18F-FMISO PET and the Eppendorf oxygen-sensitive electrode. Acta Oncol, 49:934–940, Oct 2010.
- [79] W. Choi, S. W. Lee, S. H. Park, J. S. Ryu, S. J. Oh, K. C. Im, E. K. Choi, J. H. Kim, S. H. Jung, S. Kim, and S. D. Ahn. Planning study for available dose of hypoxic tumor volume using fluorine-18-labeled fluoromisonidazole positron emission tomography for treatment of the head and neck cancer. *Radiother Oncol*, 97:176–182, Nov 2010.
- [80] K. S. Chao, W. R. Bosch, S. Mutic, J. S. Lewis, F. Dehdashti, M. A. Mintun, J. F. Dempsey, C. A. Perez, J. A. Purdy, and M. J. Welch. A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensity-modulated radiation therapy. *Int. J. Radiat. Oncol. Biol. Phys.*, 49:1171–1182, Mar 2001.
- [81] N. Y. Lee, J. G. Mechalakos, S. Nehmeh, Z. Lin, O. D. Squire, S. Cai, K. Chan, P. B. Zanzonico, C. Greco, C. C. Ling, J. L. Humm, and H. Schoder. Fluorine-18-labeled fluoromisonidazole positron emission and computed tomography-guided intensity-modulated radiotherapy for head and neck cancer: a feasibility study. *Int. J. Radiat. Oncol. Biol. Phys.*, 70:2–13, Jan 2008.

BIBLIOGRAPHY xiii

[82] M. Alber, F. Paulsen, S. M. Eschmann, and H. J. Machulla. On biologically conformal boost dose optimization. *Phys Med Biol*, 48:N31–35, Jan 2003.

- [83] S. M. Bentzen and V. Gregoire. Molecular imaging-based dose painting: a novel paradigm for radiation therapy prescription. Semin Radiat Oncol, 21:101–110, Apr 2011.
- [84] F. Duprez, W. De Neve, W. De Gersem, M. Coghe, and I. Madani. Adaptive dose painting by numbers for head-and-neck cancer. Int. J. Radiat. Oncol. Biol. Phys., 80:1045–1055, Jul 2011.
- [85] I. Madani, F. Duprez, T. Boterberg, C. Van de Wiele, K. Bonte, P. Deron, W. De Gersem, M. Coghe, and W. De Neve. Maximum tolerated dose in a phase I trial on adaptive dose painting by numbers for head and neck cancer. *Radiother Oncol*, 101:351–355, Dec 2011.
- [86] R. T. Flynn, S. R. Bowen, S. M. Bentzen, T. Rockwell Mackie, and R. Jeraj. Intensity-modulated x-ray (IMXT) versus proton (IMPT) therapy for theragnostic hypoxia-based dose painting. *Phys Med Biol*, 53:4153–4167, Aug 2008.
- [87] S. R. Bowen, R. T. Flynn, S. M. Bentzen, and R. Jeraj. On the sensitivity of IMRT dose optimization to the mathematical form of a biological imaging-based prescription function. *Phys Med Biol*, 54:1483–1501, Mar 2009.
- [88] R. T. Flynn, D. L. Barbee, T. R. Mackie, and R. Jeraj. Comparison of intensity modulated x-ray therapy and intensity modulated proton therapy for selective subvolume boosting: a phantom study. Phys Med Biol, 52:6073–6091, Oct 2007.
- [89] D. Thorwarth, S. M. Eschmann, F. Paulsen, and M. Alber. Hypoxia dose painting by numbers: a planning study. Int. J. Radiat. Oncol. Biol. Phys., 68:291–300, May 2007.
- [90] D. Thorwarth, S. M. Eschmann, F. Paulsen, and M. Alber. A kinetic model for dynamic [18F]-Fmiso PET data to analyse tumour hypoxia. *Phys Med Biol*, 50:2209–2224, May 2005.
- [91] D. Thorwarth, S. M. Eschmann, J. Scheiderbauer, F. Paulsen, and M. Alber. Kinetic analysis of dynamic 18F-fluoromisonidazole PET correlates with radiation treatment outcome in head-andneck cancer. BMC Cancer, 5:152, 2005.
- [92] D. Thorwarth and M. Alber. [Individualised radiotherapy on the basis of functional imaging with FMISO PET]. Z Med Phys, 18:43–50, 2008.
- [93] A. Dasu, I. Toma-Dasu, and M. Karlsson. Theoretical simulation of tumour oxygenation and results from acute and chronic hypoxia. *Phys Med Biol*, 48:2829–2842, Sep 2003.
- [94] J. Overgaard. Hypoxic modification of radiotherapy in squamous cell carcinoma of the head and neck-a systematic review and meta-analysis. *Radiother Oncol*, 100:22–32, Jul 2011.
- [95] E. Lartigau, A. Lusinchi, P. Weeger, P. Wibault, B. Luboinski, F. Eschwege, and M. Guichard. Variations in tumour oxygen tension (pO2) during accelerated radiotherapy of head and neck carcinoma. Eur. J. Cancer, 34:856–861, May 1998.
- [96] P. Stadler, H. J. Feldmann, C. Creighton, R. Kau, and M. Molls. Changes in tumor oxygenation during combined treatment with split-course radiotherapy and chemotherapy in patients with head and neck cancer. *Radiother Oncol*, 48:157–164, Aug 1998.

xiv BIBLIOGRAPHY

[97] A. Becker, G. Hansgen, C. Richter, and J. Dunst. [Oxygenation status of squamous cell carcinoma of the head and neck: comparison of primary tumors, their neck node metastases and normal tissue]. Strahlenther Onkol, 174:484–486, Sep 1998.

- [98] E. Lartigau, A. M. Le Ridant, P. Lambin, P. Weeger, L. Martin, R. Sigal, A. Lusinchi, B. Luboinski, F. Eschwege, and M. Guichard. Oxygenation of head and neck tumors. *Cancer*, 71:2319–2325, Apr 1993.
- [99] M. Nordsmark, S. M. Bentzen, V. Rudat, D. Brizel, E. Lartigau, P. Stadler, A. Becker, M. Adam, M. Molls, J. Dunst, D. J. Terris, and J. Overgaard. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother Oncol, 77:18–24, Oct 2005.
- [100] S. M. Eschmann, F. Paulsen, C. Bedeshem, H. J. Machulla, T. Hehr, M. Bamberg, and R. Bares. Hypoxia-imaging with (18)F-Misonidazole and PET: changes of kinetics during radiotherapy of head-and-neck cancer. *Radiother Oncol*, 83:406–410, Jun 2007.
- [101] K. Lehtio, O. Eskola, T. Viljanen, V. Oikonen, T. Gronroos, L. Sillanmaki, R. Grenman, and H. Minn. Imaging perfusion and hypoxia with PET to predict radiotherapy response in head-andneck cancer. *Int. J. Radiat. Oncol. Biol. Phys.*, 59:971–982, Jul 2004.
- [102] S. A. Nehmeh, N. Y. Lee, H. Schroder, O. Squire, P. B. Zanzonico, Y. E. Erdi, C. Greco, G. Mageras, H. S. Pham, S. M. Larson, C. C. Ling, and J. L. Humm. Reproducibility of intratumor distribution of (18)F-fluoromisonidazole in head and neck cancer. *Int. J. Radiat. Oncol. Biol. Phys.*, 70:235–242, Jan 2008.
- [103] D. Thorwarth, S. M. Eschmann, F. Holzner, F. Paulsen, and M. Alber. Combined uptake of [18F]FDG and [18F]FMISO correlates with radiation therapy outcome in head-and-neck cancer patients. *Radiother Oncol*, 80:151–156, Aug 2006.
- [104] Ivan E. Sutherland, Robert F. Sproull, and Robert A. Schumacker. A characterization of ten hidden-surface algorithms. ACM Comput. Surv., 6:1–55, March 1974.
- [105] K. D. Hunter, E. K. Parkinson, and P. R. Harrison. Profiling early head and neck cancer. Nat. Rev. Cancer, 5:127–135, Feb 2005.
- [106] B. Brockenstein and G. Masters. Head and neck cancer. Kluwer Academic Publishers, 2003.
- [107] NCIC Clinical Trials Group. Radiation therapy and cisplatin or panitumumab in treating patients with locally advanced stage iii or stage iv head and neck cancer. 2011.
- [108] N. Christian, J. A. Lee, A. Bol, M. De Bast, B. Jordan, and V. Gregoire. The limitation of PET imaging for biological adaptive-IMRT assessed in animal models. *Radiother Oncol*, 91:101–106, Apr 2009.
- [109] S. F. Petit, A. L. Dekker, R. Seigneuric, L. Murrer, N. A. van Riel, M. Nordsmark, J. Overgaard, P. Lambin, and B. G. Wouters. Intra-voxel heterogeneity influences the dose prescription for dose-painting with radiotherapy: a modelling study. *Phys Med Biol*, 54:2179–2196, Apr 2009.
- [110] M. Nordsmark, S. M. Bentzen, and J. Overgaard. Measurement of human tumour oxygenation status by a polarographic needle electrode. An analysis of inter- and intratumour heterogeneity. *Acta Oncol.* 33:383–389, 1994.

BIBLIOGRAPHY xv

- [111] T. Bortfeld. IMRT: a review and preview. Phys Med Biol, 51:R363–379, Jul 2006.
- [112] S. W. Lee, G. M. Back, B. Y. Yi, E. K. Choi, S. D. Ahn, S. S. Shin, J. H. Kim, S. Y. Kim, B. J. Lee, S. Y. Nam, S. H. Choi, S. B. Kim, J. H. Park, K. K. Lee, S. H. Park, and J. H. Kim. Preliminary results of a phase I/II study of simultaneous modulated accelerated radiotherapy for nondisseminated nasopharyngeal carcinoma. *Int. J. Radiat. Oncol. Biol. Phys.*, 65:152–160, May 2006.
- [113] M. Nordsmark and J. Overgaard. Tumor hypoxia is independent of hemoglobin and prognostic for loco-regional tumor control after primary radiotherapy in advanced head and neck cancer. *Acta Oncol*, 43:396–403, 2004.
- [114] N. Lee, S. Nehmeh, H. Schoder, M. Fury, K. Chan, C. C. Ling, and J. Humm. Prospective trial incorporating pre-/mid-treatment [18F]-misonidazole positron emission tomography for head-andneck cancer patients undergoing concurrent chemoradiotherapy. *Int. J. Radiat. Oncol. Biol. Phys.*, 75:101–108, Sep 2009.
- [115] Z. Lin, J. Mechalakos, S. Nehmeh, H. Schoder, N. Lee, J. Humm, and C. C. Ling. The influence of changes in tumor hypoxia on dose-painting treatment plans based on 18F-FMISO positron emission tomography. *Int. J. Radiat. Oncol. Biol. Phys.*, 70:1219–1228, Mar 2008.
- [116] A. Sovik, E. Malinen, H. K. Skogmo, S. M. Bentzen, O. S. Bruland, and D. R. Olsen. Radiotherapy adapted to spatial and temporal variability in tumor hypoxia. *Int. J. Radiat. Oncol. Biol. Phys.*, 68:1496–1504, Aug 2007.

xvi BIBLIOGRAPHY

## List of Figures

2.1	Overview on the physical effect responsible for the energy loss of photons in matter.	
	Photoelectric effect (left), Compton effect (middle) and Pair production (right)	3
2.2	Total cross section $\mu$ in units of barn $(10^{-28} \text{m}^2)$ in the region from 1 eV up to 10 GeV.	
	For radiotherapy, the Compton effect is most prevalent, as the common energies are in	
	the range of a few MeV	7
2.3	Damage mechanism of single and double strand breaks in DNA through ionizing radiation.	
	Single stand breaks are only assigned to radiation damage that is created by one particle	
	track, while double stand breaks are generated either by two seperate single tracks or a	
	single track creating single strand breaks in two DNA strands	10
2.4	HIF-1 $\alpha$ mechanism for the transcription of proteins in DNA that increase cell survival in	
	tumour cells in hypoxic environments	13
2.5	HRF model fit to original data from Carlson et al. [25]. The new fit to the original data	
	allowed an estimate on the error on $K$ and $m$ for the robustness analysis in the later part	
	of this work	17
3.1	Total cross section $\mu$ in units of barn $(10^{-28} \text{m}^2)$ in the region from 1 eV up to 10 GeV.	
	For radiotherapy, the Compton effect is most prevalent, as the common energies are in	
	the range of a few MeV	25
3.2	Chemical structure of common tracers used in PET. FMISO and Cu-ATSM are commonly	
	used in current studies, while studies with FAZA, FETA and FETNIM are on the way.	
	FDG can be administered as a hypoxia tracer but is usually deployed for the use staging.	28
3.3	Retention mechanism of FMISO in the environment of oxygen. Figure adopted from	
	Krohn et a. [54]	29
3.4	Transformation of FMISO PET SUV to oxygen partial pressure derived from the param-	
	eters of the model developed by Chang et al. [69] . Dotted and dashed line show the	
	impact of the error of the model parameter $p_{50}=6.4\pm5.4$ mmHg with due regard to the	
	steepness of the transformation function.	32
4.1	Dose volume histograms for the GTV of the clinical plan (green) and all volumes from	
	biological dose painting: GTV (red), GTV $_{5.0}$ (blue), GTV $_{2.5}$ (magenta). Patient 2 did	
	not have a $\mathrm{GTV}_{2.5}$ as the GTV was to small	53

xviii LIST OF FIGURES

4.2	Ratio R of delivered biological effect in the GTV divided by the prescribed effect. If $R > 1$ ,	
	the voxel is over dose, while $R < 1$ can be interpreted as under dose. $R$ distributions	
	show clinical plan (green) and dose painted plan (red)	55
4.3	eDVH of GTV for all treated patients with biological dose painting. The biological	
	effect of the delivered plan (blue) reduced through hypoxia is based on the clinical plan	
	(green). Dose painting (red) is able to compensate for hypoxia by increasing the dose	
	to such volumes. The dip in the eDVH for the delivered plan (blue) stems from the $2.5$	
	mmHg hypoxia level	57
5.1	Impact of model uncertainties on the HRF derived from the signal of a PET FMISO	
	image in the SUV range of 0 up to 3.17. The lowest impact on the HRF prescriptions is	
	seen with $K$ , while $p_{50}$ and $m$ introduces the largest HRF changes in the transformation	
	model	62
5.2	Impact of model parameters uncertainties on the eDVH for patient 1 based on the ap-	
	proved biological dose painted plan with mean values for $K$ , $m$ and $p_{50}$	65

## List of Tables

2.1	result parameters for organs at risk derived from various studies	11
2.2	Tissue parameters for tumor tissue derived from various studies	12
2.3	Model parameters from different in vivo and in vitro studies. All studies used photons	
	as radiation source to derive parameter data. Remarks: *Ehrlich ascites tumor cells,	
	$^{\#}$ Values and error recalculated from original data and fit, $^{\&}$ not included in combined	
	value since no error was available. Error from the Carlson et al. was not available in	
	the published article and has been calculated through a new fit with the original data	
	supplied by David Carlson (cf. figure 2.5)	16
3.1	pO2 values for different head and neck studies. All pO2 values were acquired with the help	
	of Eppendorf polarographic needle measurements (if not stated otherwise). Errors are	
	standard deviation of the given data and sample size. Combined data are gather through	
	weight of standard deviation and number of patients screened. $\mathbf{C}=\mathbf{Combined}$ (Tumor	
	& Nodes), LN = Lymphnodes, M = Muscle Tissue, PT = Primary Tumor. Remarks: *	
	$\leq$ 2.0 mmHg, $^{\#}$ not including muscle tissue pO2 values $\ \ldots \ \ldots \ \ldots \ \ldots \ \ldots$	43
3.2	Uptake values for FMISO and FDG PET images from different studies and measure-	
	ments conducted in head and neck patients. Errors are standard deviation from data	
	in corresponding study. Remarks: * Combined SUV uptake (Primary Tumor Volume $\&$	
	Lymphnodes), ** Metastasis/Lymph Nodes, ** Primary Tumor	45
3.3	HRF values for different hypoxic regions in head and neck patients. Parameters for	
	calculations for HRF $_0$ are $m=2.82\pm0.05$ and $K=1.94\pm0.13$ mmHg. Errors calculated	
	via error propagation method	46
4.1	Patient information columns show patient ID as well as the size of the treated GTV in ccm.	
	Hypoxic volume column sizes of $GTV_{5.0}$ and $GTV_{2.5}$ are based on the $GTV$ (=100%) created through application of negative safety margins. The guidance values for the	
	hypoxic sub volume construction are $GTV_{2.5} = 16.08 \pm 4.65$ and $GTV_{5.0} = 36.38 \pm 6.80$ .	
	Clinical plan columns show the mean dose and maximum dose in the GTV. Biological dose	
	painting columns show the theoretical dose values for equal biological effect due to HRF.	
	HRF values are HRF <sub>2.5</sub> = 1.8 (GTV <sub>2.5</sub> ), HRF <sub>5.0</sub> = 1.51 (GTV <sub>5.0</sub> ) and HRF <sub>10.0</sub> = 1.3	
	(GTV)	51